Unnamed: 0,title,date,stock,sentiment
1128115.0,"Cramer Shares His Thoughts On Marriott, Tegna And More",2020-06-10 10:36:00-04:00,SGEN,positive
1128116.0,"Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $175",2020-06-01 11:54:00-04:00,SGEN,neutral
1128117.0,Seattle Genetics Reports Results From Exploratory Analyses Of HER2CLIMB For TUKYSA In Brain Metastases Patients With HER2-Positive Breast Cancer,2020-05-29 08:23:00-04:00,SGEN,negative
1128118.0,"Benzinga's Top Upgrades, Downgrades For May 26, 2020",2020-05-26 09:42:00-04:00,SGEN,positive
1128119.0,Seattle Genetics shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and a $185 price target.,2020-05-26 09:16:00-04:00,SGEN,positive
1128120.0,"JMP Securities Initiates Coverage On Seattle Genetics with Market Outperform Rating, Announces Price Target of $185",2020-05-26 08:52:00-04:00,SGEN,positive
1128121.0,Seattle Genetics Reports ADCETRIS Receives European Commission Approval For Treatment Of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma,2020-05-14 08:29:00-04:00,SGEN,positive
1128122.0,Seattle Genetics Reports TUKYSA Approval For Treatment Of Patients With Metastatic HER2-Positive Breast Cancer In Switzerland,2020-05-12 08:01:00-04:00,SGEN,negative
1128123.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,SGEN,positive
1128124.0,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,2020-05-05 12:44:00-04:00,SGEN,positive
1128125.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,SGEN,neutral
1128126.0,"Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to $149",2020-05-04 08:14:00-04:00,SGEN,neutral
1128127.0,"CFRA Maintains Sell on Seattle Genetics, Raises Price Target to $129",2020-05-01 11:37:00-04:00,SGEN,neutral
1128128.0,Seattle Genetics shares are trading higher after the company reported better-than-expected Q1 sales. Guggenheim upgraded the stock from Neutral to Buy.,2020-05-01 10:38:00-04:00,SGEN,positive
1128129.0,Morning Market Stats in 5 Minutes,2020-05-01 10:37:00-04:00,SGEN,neutral
1128130.0,Stocks That Hit 52-Week Highs On Friday,2020-05-01 10:33:00-04:00,SGEN,neutral
1128131.0,"Benzinga's Top Upgrades, Downgrades For May 1, 2020",2020-05-01 09:40:00-04:00,SGEN,positive
1128132.0,"RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to $149",2020-05-01 09:18:00-04:00,SGEN,neutral
1128133.0,"Stifel Maintains Hold on Seattle Genetics, Raises Price Target to $127",2020-05-01 08:52:00-04:00,SGEN,neutral
1128134.0,"HC Wainwright & Co. Maintains Buy on Seattle Genetics, Raises Price Target to $175",2020-05-01 07:17:00-04:00,SGEN,neutral
1128135.0,"Needham Maintains Buy on Seattle Genetics, Raises Price Target to $163",2020-05-01 07:06:00-04:00,SGEN,neutral
1128136.0,"SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $155",2020-05-01 07:03:00-04:00,SGEN,neutral
1128137.0,Guggenheim Upgrades Seattle Genetics to Buy,2020-05-01 06:36:00-04:00,SGEN,neutral
1128138.0,"CORRECTION: Seattle Genetics Q1 Total Sales $234.5M, Beats Estimate",2020-04-30 16:04:00-04:00,SGEN,neutral
1128139.0,"Seattle Genetics Q1 EPS $(0.980) Misses $(0.790) Estimate, Sales $198.500M Miss $207.140M Estimate",2020-04-30 16:03:00-04:00,SGEN,negative
1128140.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,SGEN,positive
1128141.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,SGEN,neutral
1128142.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,SGEN,neutral
1128143.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,SGEN,negative
1128144.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,SGEN,positive
1128145.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,SGEN,positive
1128146.0,"BMO Capital Reiterates Outperform on Seattle Genetics, Raises Price Target to $154",2020-04-20 13:01:00-04:00,SGEN,neutral
1128147.0,"SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $146",2020-04-20 12:08:00-04:00,SGEN,neutral
1128148.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,SGEN,neutral
1128149.0,"Stifel Maintains Hold on Seattle Genetics, Raises Price Target to $120",2020-04-20 10:19:00-04:00,SGEN,neutral
1128150.0,"Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $146",2020-04-20 08:57:00-04:00,SGEN,neutral
1128151.0,"RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to $147",2020-04-20 08:17:00-04:00,SGEN,neutral
1128152.0,10 Biggest Price Target Changes For Monday,2020-04-20 08:08:00-04:00,SGEN,neutral
1128153.0,Shares of Seattle Genetics are trading higher after analysts at Needham reiterated a buy rating on the stock and raised their price target to $157.,2020-04-20 07:47:00-04:00,SGEN,positive
1128154.0,"Needham Maintains Buy on Seattle Genetics, Raises Price Target to $157",2020-04-20 06:49:00-04:00,SGEN,neutral
1128155.0,Seattle Genetics Press Release Confirms Earlier Report From FDA Of Approval For TUKYSA For Advanced Unresectable or Metastatic HER2-Positive Breast Cancer,2020-04-17 14:30:00-04:00,SGEN,negative
1128156.0,"Seattle Genetics Shares Sell Off From Session High, Down ~1.5% From Session High",2020-04-17 14:08:00-04:00,SGEN,positive
1128157.0,"UPDATE: FDA Says, As Part Of Project Orbis, Granted Approval Of Seattle Genetics' Tukysa Breast Cancer Treatment",2020-04-17 13:59:00-04:00,SGEN,negative
1128158.0,"Seattle Genetics Shares Spike To Session High, Up 0.8%, Amid Report FDA Approved First New Drug Under Int'l. Collaboration, A Treatment For Patients With HER2-Positive Metastatic Breast Cancer",2020-04-17 13:58:00-04:00,SGEN,negative
1128159.0,"FDA Approves Tukysa, Tucatinib",2020-04-17 13:44:00-04:00,SGEN,positive
1128160.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,SGEN,neutral
1128161.0,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",2020-04-17 07:35:00-04:00,SGEN,positive
1128162.0,Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.,2020-04-16 12:38:00-04:00,SGEN,positive
1128163.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-16 10:19:00-04:00,SGEN,neutral
1128164.0,"Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to $111",2020-04-15 10:45:00-04:00,SGEN,neutral
1128165.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,SGEN,positive
1128166.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,SGEN,neutral
1128167.0,"The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation",2020-04-07 07:55:00-04:00,SGEN,negative
1128168.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,SGEN,positive
1128169.0,Seattle Genetics Announces Potential Accelerated Approval Pathway In The US For Padcev In Combination With Immune Therapy Pembrolizumab As First-line Treatment For Advanced Urothelial Cancer,2020-04-02 08:03:00-04:00,SGEN,positive
1128170.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,SGEN,positive
1128171.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,SGEN,positive
1128172.0,Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:16:00-05:00,SGEN,positive
1128173.0,Seattle Genetics shares are trading lower. Traders attribute weakness to positive trial results from competitor Merck's KEYNOTE-204 trial of Keytruda.,2020-03-02 09:21:00-05:00,SGEN,positive
1128174.0,"Seattle Genetics Cancels Out of Cowen Healthcare Conference, Blames Coronavirus",2020-03-02 08:06:00-05:00,SGEN,negative
1128175.0,Seattle Genetics shares are trading higher potentially on a rebound with the overall market after it traded lower on Tuesday amid coronavirus fears.,2020-02-26 10:52:00-05:00,SGEN,negative
1128176.0,Seattle Genetics And Astellas Received FDA Breakthrough Therapy Designation For Its PADCEV In Combination With Pembrolizumab In First-Line Advanced Bladder Cancer,2020-02-19 08:35:00-05:00,SGEN,negative
1128177.0,"Benzinga's Top Upgrades, Downgrades For February 18, 2020",2020-02-18 10:11:00-05:00,SGEN,positive
1128178.0,A Peek Into The Markets: US Stock Futures Drop After Apple Warning,2020-02-18 06:02:00-05:00,SGEN,negative
1128179.0,"Barclays Downgrades Seattle Genetics to Equal-Weight, Announces $124 Price Target",2020-02-18 05:08:00-05:00,SGEN,neutral
1128180.0,Seattle Genetics Reports FDA Filing Acceptance For Priority Review Of Tucatinib New Drug Application,2020-02-13 08:00:00-05:00,SGEN,positive
1128181.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,SGEN,positive
1128182.0,"H.C. Wainwright Reiterates Buy on Seattle Genetics, Raises Price Target to $150",2020-02-12 07:26:00-05:00,SGEN,neutral
1128183.0,Seattle Genetics shares are trading higher after the company announced an update to its Phase 1b/2 trial of PADCEV. Goldman Sachs also maintained a Buy rating on the stock and increased its price target from $126 to $165 per share.,2020-02-11 11:49:00-05:00,SGEN,positive
1128184.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,SGEN,neutral
1128185.0,"Goldman Sachs Maintains Buy on Seattle Genetics, Raises Price Target to $165",2020-02-11 08:47:00-05:00,SGEN,neutral
1128186.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,SGEN,positive
1128187.0,"Seattle Genetics And Astellas Announce Updated Results From Phase 1b/2 Trial Of PADCEV; After Median Follow-Up, 73% Of Patients Had Confirmed Tumor Response With Majority Of Responses Still Ongoing, No New Safety Signals Observed",2020-02-10 17:01:00-05:00,SGEN,negative
1128188.0,Seattle Genetics shares are trading lower potentially on profit-taking after the stock rallied roughly 6% following Q4 earnings.,2020-02-10 10:53:00-05:00,SGEN,neutral
1128189.0,Seattle Genetics shares are trading lower following Q4 earnings results. The company's Adcetris sales came in below consensus estimates while 2020 guidance was also soft.,2020-02-07 10:09:00-05:00,SGEN,neutral
1128190.0,Seattle Genetics shares are trading lower after the company reported Q4 earnings results.,2020-02-06 16:30:00-05:00,SGEN,neutral
1128191.0,"Seattle Genetics Q4 Adj. EPS $(0.14) Up From $(0.75) YoY, Sales $289.8M Beat $224.5M Estimate",2020-02-06 16:19:00-05:00,SGEN,neutral
1128192.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,SGEN,negative
1128193.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,SGEN,positive
1128194.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,SGEN,neutral
1128195.0,Seattle Genetics Reports EMA Validation For Co.'s Marketing Authorization Application For Tucatinib For Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer,2020-01-31 08:05:00-05:00,SGEN,negative
1128196.0,"Benzinga's Top Upgrades, Downgrades For January 28, 2020",2020-01-28 09:43:00-05:00,SGEN,positive
1128197.0,"BMO Capital Initiates Coverage On Seattle Genetics with Outperform Rating, Announces $139 Price Target",2020-01-28 06:54:00-05:00,SGEN,neutral
1128198.0,"Seattle Genetics shares are trading lower in sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 people.",2020-01-27 11:36:00-05:00,SGEN,negative
1128199.0,Seattle Genetics Achieves Milestone Following European Commission Approval Of Roche's Polivy,2020-01-21 08:02:00-05:00,SGEN,positive
1128200.0,"Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Lowers Price Target to $115",2020-01-17 08:30:00-05:00,SGEN,negative
1128201.0,Seattle Genetics shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-01-14 13:52:00-05:00,SGEN,positive
1128202.0,Guggenheim Securities Downgrades Seattle Genetics to Neutral,2020-01-02 08:02:00-05:00,SGEN,positive
1128203.0,Seattle Genetics Announces Submission Of Tucatinib New Drug Application To FDA For Patients With Locally Advanced Or Metastatic HER2-Positive Breast Cancer,2019-12-23 08:07:00-05:00,SGEN,negative
1128204.0,"The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions",2019-12-22 12:08:00-05:00,SGEN,positive
1128205.0,Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod,2019-12-19 09:07:00-05:00,SGEN,negative
1128206.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,SGEN,neutral
1128207.0,Seattle Genetics shares are trading higher after the FDA granted accelerated approval to its PADCEV for the treatment of adult patients with locally advanced or metastatic urothelial cancer.,2019-12-19 08:26:00-05:00,SGEN,positive
1128208.0,28 Stocks Moving in Thursday's Pre-Market Session,2019-12-19 08:13:00-05:00,SGEN,neutral
1128209.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,SGEN,negative
1128210.0,FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV for People with Locally Advanced or Metastatic Urothelial Cancer,2019-12-19 05:17:00-05:00,SGEN,positive
1128211.0,Seattle Genetics Announces US FDA Grants Breakthrough Therapy Designation For Tucatinib In Locally Advanced Or Metastatic HER2-Positive Breast Cancer,2019-12-18 08:09:00-05:00,SGEN,negative
1128212.0,Shares of healthcare companies are trading higher on reports suggesting Congress will permanently repeal three major Obamacare-related health industry taxes as part of fiscal 2020 spending bills.,2019-12-16 12:48:00-05:00,SGEN,positive
1128213.0,"Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $124",2019-12-12 09:26:00-05:00,SGEN,neutral
1128214.0,"'SGEN Tucatinib pivotal HER2CLIMB data out at #SABC19 Beautiful PFS and OS curves and great news for MBC patients! #BCSM PFS HR=0.54 OS  HR=0.66
Another amazing drug out of $ARRY's powerful discovery machine!' -Tweet From Andy Biotech",2019-12-11 09:55:00-05:00,SGEN,positive
1128215.0,Seattle Genetics Highlights Presentation Of Tucatinib HER2CLIMB Trial Results,2019-12-11 09:55:00-05:00,SGEN,neutral
1128216.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,SGEN,negative
1128217.0,"UPDATE: Morgan Stanley Initiates Seattle Genetics With Equal-Weight, $123 Target Notes '2019 has been a pivotal year with upside data on the pipeline beyond lead asset Adcetris'; Equal-Weight, $123 Target Reflects 'current high expectations'",2019-12-10 12:24:00-05:00,SGEN,positive
1128218.0,"Benzinga's Top Upgrades, Downgrades For December 10, 2019",2019-12-10 09:47:00-05:00,SGEN,positive
1128219.0,"Morgan Stanley Initiates Coverage On Seattle Genetics with Equal-Weight Rating, Announces $123 Price Target",2019-12-10 08:39:00-05:00,SGEN,neutral
1128220.0,"Seattle Genetics, Takeda Report Added Analyses Of ADCETRIS ECHELON-1, ECHELON-2 Phase 3 Trials At ASH",2019-12-09 10:03:00-05:00,SGEN,neutral
1128221.0,Seattle Genetics Announces Updated Data of ADCETRIS in Combination with OPDIVO in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH ASH 2019,2019-12-07 14:23:00-05:00,SGEN,neutral
1128222.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,SGEN,positive
1128223.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,SGEN,negative
1128224.0,Seattle Genetics Announces Collaboration with Merck to Evaluate its Enfortumab in Combination with KEYTRUDA,2019-12-02 08:01:00-05:00,SGEN,neutral
1128225.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,SGEN,positive
1128226.0,Seattle Genetics Reports Health Canada Approval Of ADCETRIS In Combo With Chemotherapy In Frontline CD30-Expressing Peripheral T-Cell Lymphoma,2019-11-25 08:06:00-05:00,SGEN,positive
1128227.0,AstraZeneca CEO: Closing In On A Cancer Cure,2019-11-22 15:39:00-05:00,SGEN,negative
1128228.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,SGEN,positive
1128229.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,SGEN,neutral
1128230.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,SGEN,positive
1128231.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,SGEN,neutral
1128232.0,Stocks That Hit 52-Week Highs On Monday,2019-11-18 11:01:00-05:00,SGEN,neutral
1128233.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,SGEN,neutral
1128234.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,SGEN,negative
1128235.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-14 10:09:00-05:00,SGEN,neutral
1128236.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,SGEN,positive
1128237.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,SGEN,neutral
1128238.0,Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership,2019-11-12 17:17:00-05:00,SGEN,negative
1128239.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,SGEN,neutral
1128240.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,SGEN,negative
1128241.0,Seattle Genetics Responds to Daiichi Sankyo's Complaint for Declaratory Judgment,2019-11-05 04:14:00-05:00,SGEN,negative
1128242.0,Seattle Genetics Narrows FY19 ADCETRIS Net Sales Guidance From $610M-$640M To $625M-$640M,2019-10-29 16:03:00-04:00,SGEN,neutral
1128243.0,"Seattle Genetics Q3 EPS $(0.55) Misses $(0.35) Estimate, Sales $213.3M Beat $211.83M Estimate",2019-10-29 16:02:00-04:00,SGEN,negative
1128244.0,Stocks That Hit 52-Week Highs On Tuesday,2019-10-29 10:52:00-04:00,SGEN,neutral
1128245.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,SGEN,positive
1128246.0,Stocks That Hit 52-Week Highs On Monday,2019-10-28 10:51:00-04:00,SGEN,neutral
1128247.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,SGEN,neutral
1128248.0,Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption,2019-10-23 16:27:00-04:00,SGEN,neutral
1128249.0,"RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to $109",2019-10-22 09:31:00-04:00,SGEN,neutral
1128250.0,UPDATE: Deutsche Bank On Seattle Genetics Also Notes 'we maintain our HOLD rating as we believe the market appropriately values the company at current levels given the recent appreciation in shares and a general lack of near-term catalysts',2019-10-22 08:58:00-04:00,SGEN,positive
1128251.0,"UPDATE: Deutsche Bank Maintains Hold On Seattle Genetics, Raises Target To $95 As Firm Notes 'We increase the probability of success for tucatinib in HER2+ breast cancer in our SGEN model from 65% to 95%'",2019-10-22 08:58:00-04:00,SGEN,positive
1128252.0,"UPDATE: H.C. Wainwright Reiterates Buy On Seattle Genetics, Raises Target To $140 As Firm Notes 'Remarkable HER2CLIMB topline positions Seattle Genetics as a strong player in breast cancer space'",2019-10-22 08:54:00-04:00,SGEN,positive
1128253.0,"Deutsche Bank Maintains Hold on Seattle Genetics, Raises Price Target to $95",2019-10-22 08:41:00-04:00,SGEN,neutral
1128254.0,"Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $110",2019-10-22 08:16:00-04:00,SGEN,neutral
1128255.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,SGEN,positive
1128256.0,"H.C. Wainwright Reiterates Buy on Seattle Genetics, Raises Price Target to $140",2019-10-22 07:41:00-04:00,SGEN,neutral
1128257.0,38 Biggest Movers From Yesterday,2019-10-22 06:42:00-04:00,SGEN,neutral
1128258.0,Mid-Afternoon Market Update: Crude Oil Down 1%; Innophos Holdings Shares Plummet,2019-10-21 16:00:00-04:00,SGEN,negative
1128259.0,33 Stocks Moving In Monday's Mid-Day Session,2019-10-21 12:32:00-04:00,SGEN,neutral
1128260.0,Mid-Day Market Update: Petmed Express Jumps On Upbeat Earnings; Infosys Shares Slide,2019-10-21 12:09:00-04:00,SGEN,positive
1128261.0,Stocks That Hit 52-Week Highs On Monday,2019-10-21 11:06:00-04:00,SGEN,neutral
1128262.0,Mid-Morning Market Update: Markets Open Higher; Halliburton Sales Miss Estimates,2019-10-21 10:43:00-04:00,SGEN,negative
1128263.0,Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study,2019-10-21 09:36:00-04:00,SGEN,negative
1128264.0,Seattle Genetics shares are trading higher following the release of positive data for the company's HER2CLIMB phase 2 trial.,2019-10-21 07:51:00-04:00,SGEN,positive
1128265.0,11 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-10-21 07:46:00-04:00,SGEN,neutral
1128266.0,26 Stocks Moving in Monday's Pre-Market Session,2019-10-21 07:41:00-04:00,SGEN,neutral
1128267.0,Stocks That Hit 52-Week Highs On Friday,2019-10-18 10:18:00-04:00,SGEN,neutral
1128268.0,4 Stocks Nearing Key Breakouts,2019-10-16 11:51:00-04:00,SGEN,neutral
1128269.0,Seattle Genetics Reports Initiation Of Phase 3 Trial Of Tucatinib In Combo With Dacyla For Patients with Advanced or Metastatic HER2-Positive Breast Cancer,2019-10-10 08:01:00-04:00,SGEN,negative
1128270.0,"Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks",2019-10-08 11:08:00-04:00,SGEN,positive
1128271.0,"UPDATE: Goldman On Puma Biotechnology Also Notes 'We believe that even if tucatinib is not differentiated on efficacy, it may garner more market share on greater tolerability based on mCRC data shown at ESMO'",2019-10-08 10:52:00-04:00,SGEN,positive
1128272.0,"A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019",2019-10-01 12:58:00-04:00,SGEN,neutral
1128273.0,10 Biggest Price Target Changes For Tuesday,2019-10-01 08:34:00-04:00,SGEN,neutral
1128274.0,"Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to $92",2019-10-01 08:16:00-04:00,SGEN,neutral
1128275.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,SGEN,negative
1128276.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,SGEN,neutral
1128277.0,"UPDATE: Piper Jaffray Maintains Overweight On Seattle Genetics, Raises Target To $95 As Firm Notes 'Early EV-103 Data Points To Broad Utility In UBC'",2019-09-30 13:37:00-04:00,SGEN,negative
1128278.0,"Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More",2019-09-30 13:13:00-04:00,SGEN,positive
1128279.0,31 Stocks Moving In Monday's Mid-Day Session,2019-09-30 13:13:00-04:00,SGEN,neutral
1128280.0,Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Benitec Biopharma Shares Slide,2019-09-30 13:12:00-04:00,SGEN,positive
1128281.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019",2019-09-30 12:05:00-04:00,SGEN,neutral
1128282.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019",2019-09-30 11:31:00-04:00,SGEN,positive
1128283.0,Stocks That Hit 52-Week Highs On Monday,2019-09-30 11:10:00-04:00,SGEN,neutral
1128284.0,Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Misses Q1 Expectations,2019-09-30 10:19:00-04:00,SGEN,negative
1128285.0,"Seattle Genetics shares are trading higher after Piper Jaffray maintained an Overweight rating on the stock and raised the price target from $75 to $95. Seattle Genetics presented compelling initial data from the EV-103 study, which compared favorably to the current standard of care. Piper Jaffray also sees the potential for further upside from additional UBS opportunities.",2019-09-30 09:41:00-04:00,SGEN,positive
1128286.0,10 Biggest Price Target Changes For Monday,2019-09-30 09:24:00-04:00,SGEN,neutral
1128287.0,"Piper Jaffray Maintains Overweight on Seattle Genetics, Raises Price Target to $95",2019-09-30 08:55:00-04:00,SGEN,negative
1128288.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,SGEN,positive
1128289.0,Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer at ESMO 2019,2019-09-28 17:32:00-04:00,SGEN,negative
1128290.0,Seattle Genetics shares are trading higher after Goldman Sachs upgraded the company's stock to Buy.,2019-09-27 09:50:00-04:00,SGEN,positive
1128291.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,SGEN,neutral
1128292.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,SGEN,negative
1128293.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,SGEN,neutral
1128294.0,Seattle Genetics Highlights Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At ESMO Congress,2019-09-17 08:16:00-04:00,SGEN,positive
1128295.0,"Seattle Genetics, Astellas Report FDA Granted Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced, Metastatic Urothelial Cancer",2019-09-16 08:10:00-04:00,SGEN,negative
1128296.0,"Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts",2019-09-12 12:51:00-04:00,SGEN,positive
1128297.0,UPDATE: Oppenheimer On Seattle Genetics Notes 'two upcoming near-term readouts could deliver value:',2019-09-12 11:22:00-04:00,SGEN,neutral
1128298.0,"UPDATE: Oppenheimer Upgrades Seattle Genetics To Outperform, Raises Target To $82 Based On Firm's Review 'of two pipeline assets (Enfortumab Vedotin and tucatinib) that focus on less competitive later lines of treatment with strong data'",2019-09-12 11:22:00-04:00,SGEN,positive
1128299.0,10 Biggest Price Target Changes For Thursday,2019-09-12 08:57:00-04:00,SGEN,neutral
1128300.0,"Oppenheimer Upgrades Seattle Genetics to Outperform, Raises Price Target to $82",2019-09-12 06:49:00-04:00,SGEN,neutral
1128301.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,SGEN,neutral
1128302.0,"Benzinga's Top Upgrades, Downgrades For August 26, 2019",2019-08-26 09:37:00-04:00,SGEN,positive
1128303.0,BTIG Initiates Coverage On Seattle Genetics with Neutral Rating,2019-08-26 08:25:00-04:00,SGEN,neutral
1128304.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,SGEN,negative
1128305.0,50 Biggest Movers From Yesterday,2019-07-25 05:50:00-04:00,SGEN,neutral
1128306.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-07-24 13:57:00-04:00,SGEN,neutral
1128307.0,24 Stocks Moving In Wednesday's Pre-Market Session,2019-07-24 07:58:00-04:00,SGEN,neutral
1128308.0,Seattle Genetics shares are trading lower after the company priced a 7.1 million share common stock offering at $70 per share.,2019-07-24 07:54:00-04:00,SGEN,positive
1128309.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,SGEN,neutral
1128310.0,Seattle Genetics Prices 7.1M Share Public Offering of Common Stock @$70/Share,2019-07-24 03:44:00-04:00,SGEN,positive
1128311.0,Seattle Genetics shares are trading lower after the company reported a 6 million share common stock offering.,2019-07-23 16:10:00-04:00,SGEN,positive
1128312.0,Seattle Genetics Reports 6M Share Common Stock Offering,2019-07-23 16:09:00-04:00,SGEN,positive
1128313.0,"Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More",2019-07-23 07:41:00-04:00,SGEN,neutral
1128314.0,60 Biggest Movers From Yesterday,2019-07-18 05:03:00-04:00,SGEN,neutral
1128315.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-07-17 12:10:00-04:00,SGEN,neutral
1128316.0,10 Biggest Price Target Changes For Wednesday,2019-07-17 09:34:00-04:00,SGEN,neutral
1128317.0,"Benzinga's Top Upgrades, Downgrades For July 17, 2019",2019-07-17 09:16:00-04:00,SGEN,positive
1128318.0,Seattle genetics shares are trading higher after the company reported better-than-expected Q2 sales results. The company also raised its collaboration and license revenue guidance from $95-$110 million to $110-$125 million.,2019-07-17 09:12:00-04:00,SGEN,positive
1128319.0,30 Stocks Moving In Wednesday's Pre-Market Session,2019-07-17 08:19:00-04:00,SGEN,neutral
1128320.0,"Piper Jaffray Upgrades Seattle Genetics to Overweight, Raises Price Target to $75",2019-07-17 06:28:00-04:00,SGEN,negative
1128321.0,"Seattle genetics shares are trading higher after the company reported better-than-expected Q2 sales results, the company also raised its collaboration and license from $95-$110 million to $110-$125 million.",2019-07-16 16:16:00-04:00,SGEN,positive
1128322.0,"Seattle Genetics Sees ADCETRIS Net Product Sales $610M-$640M, Raises Collaboration And License Revenue Guidance From $95M-$110M To $110M-$125M",2019-07-16 16:03:00-04:00,SGEN,neutral
1128323.0,"Seattle Genetics Q2 EPS $(0.49) Misses $(0.38) Estimate, Sales $218.45M Beat $189.81M Estimate",2019-07-16 16:02:00-04:00,SGEN,negative
1128324.0,Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer,2019-07-16 08:24:00-04:00,SGEN,negative
1128325.0,"Earnings Scheduled For July 16, 2019",2019-07-16 04:12:00-04:00,SGEN,neutral
1128326.0,The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings,2019-07-13 17:04:00-04:00,SGEN,neutral
1128327.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,SGEN,negative
1128328.0,Shares of several healthcare companies in the pharmaceutical space are trading lower after Amneal Pharmaceuticals announced a cost reduction plan in response to the continuing industry challenges. Amneal cut guidance as part of plan.,2019-07-10 11:37:00-04:00,SGEN,negative
1128329.0,Seattle Genetics Option Alert: Jul 19 $70 Calls at the Ask: 1690 @ $2.15 vs 1575 OI; Ref=$67.925,2019-07-09 10:15:00-04:00,SGEN,positive
1128330.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,SGEN,positive
1128331.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,SGEN,positive
1128332.0,Consider These New ETFs In A Megatrend Search,2019-06-14 15:37:00-04:00,SGEN,neutral
1128333.0,Seattle Genetics Announces Multiple ADCETRIS Presentations At Congress Of The European Hematology Association And The International Conference On Malignant Lymphoma Jun. 13-16,2019-06-12 08:06:00-04:00,SGEN,neutral
1128334.0,"Seattle Genetics Highlights FDa Approval Of Genentech's Polivy, Which Utilizes The Company's Antibody-Drug Conjugate Technology",2019-06-10 12:52:00-04:00,SGEN,positive
1128335.0,"Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.",2019-06-03 09:32:00-04:00,SGEN,positive
1128336.0,"Seattle Genetics Reports Added Analyses Of ECHELON-1, ECHELON-2 Phase 3 Trials Of ADCETRIS At ASCO",2019-06-03 08:01:00-04:00,SGEN,neutral
1128337.0,Seattle Genetics Gives an Update on its Phase 2 Trial EV-201,2019-06-03 07:35:00-04:00,SGEN,neutral
1128338.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,SGEN,neutral
1128339.0,Seattle Genetics shares trading higher given overall strength in the biotech space. Not seeing company-specific news to justify the move higher.,2019-05-21 11:39:00-04:00,SGEN,positive
1128340.0,Seattle Genetics shares are trading higher after the company highlighted presentations of new clinical data from multiple studies of novel targeted therapies at the ASCO annual meeting.,2019-05-16 11:14:00-04:00,SGEN,positive
1128341.0,Seattle Genetics Highlights Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology,2019-05-15 17:11:00-04:00,SGEN,positive
1128342.0,"Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.",2019-05-13 10:35:00-04:00,SGEN,negative
1128343.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,SGEN,positive
1128344.0,Seattle Genetics Says Health Canada Approves ADCETRIS For The Treatment Of Previously Untreated Hodgkin Lymphoma,2019-05-03 12:10:00-04:00,SGEN,positive
1128345.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,SGEN,negative
1128346.0,Seattle Genetics shares trading lower following below-consensus Q1 ADCETRIS sales of $135 million and royalties of $15.6 million.,2019-04-26 10:45:00-04:00,SGEN,neutral
1128347.0,"The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug",2019-04-26 08:02:00-04:00,SGEN,negative
1128348.0,Seattle Genetics Reaffirms FY19 ADCETRIS Sales $610M-$640M,2019-04-25 16:08:00-04:00,SGEN,neutral
1128349.0,"Seattle Genetics Q1 EPS $(0.08) Beats $(0.29) Estimate, Sales $195.199M Beat $186.77M Estimate",2019-04-25 16:04:00-04:00,SGEN,neutral
1128350.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,SGEN,neutral
1128351.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,SGEN,neutral
1128352.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,SGEN,negative
1128353.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,SGEN,positive
1128354.0,Seattle Genetics shares are trading lower after analysts at Stifel Nicolaus initiated coverage on the stock with a Hold rating and a $70 price target.,2019-04-11 12:45:00-04:00,SGEN,neutral
1128355.0,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",2019-04-11 09:09:00-04:00,SGEN,positive
1128356.0,"Stifel Nicolaus Initiates Coverage On Seattle Genetics with Hold Rating, Announces $70 Price Target",2019-04-11 07:21:00-04:00,SGEN,neutral
1128357.0,54 Biggest Movers From Friday,2019-04-08 05:11:00-04:00,SGEN,neutral
1128358.0,40 Stocks Moving In Friday's Mid-Day Session,2019-04-05 12:30:00-04:00,SGEN,neutral
1128359.0,"Seattle Genetics shares are trading higher after RBC raised its price target from $89 to $90; noting that Merck pushing their estimated KEYNOTE-204 trial completion date from ""any day now"" to 2023 removes competitve overhang on Seattle's shares.",2019-04-05 10:18:00-04:00,SGEN,positive
1128360.0,"Seattle Genetics Reports Completion Of Enrollment In Phase 2 Trial Of Tisotumab Vedotin In Recurrent, Metastatic Cervical Cancer",2019-03-29 08:05:00-04:00,SGEN,negative
1128361.0,Seattle Genetics shares are trading higher after the company reported positive topline data from its pivotal trial of Enfortumab for urothelial cancer.,2019-03-28 09:10:00-04:00,SGEN,positive
1128362.0,"Seattle Genetics, Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer",2019-03-28 03:47:00-04:00,SGEN,positive
1128363.0,"Benzinga's Top Upgrades, Downgrades For March 27, 2019",2019-03-27 09:17:00-04:00,SGEN,positive
1128364.0,"Berenberg Initiates Coverage On Seattle Genetics with Buy Rating, Announces $95 Price Target",2019-03-27 08:38:00-04:00,SGEN,neutral
1128365.0,Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At American Association For Cancer Research (AACR) Annual Meeting,2019-03-27 08:11:00-04:00,SGEN,negative
1128366.0,Seattle Genetics Option Alert: Apr 18 $80 Calls Sweep (33) near the Ask: 737 @ $1.601 vs 483 OI; Earnings 4/25 After Close [est] Ref=$74.71,2019-03-26 14:16:00-04:00,SGEN,positive
1128367.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,SGEN,positive
1128368.0,"13F From Ken Griffin's Citadel Advisors Shows New Stakes In Booking Holdings, Seattle Genetics, Macy's, Anaplan, Assurant, Cut Stakes In Morgan Stanley, Lowe's, Netflix, Visa, Lockheed Martin, Capital One, Microchip",2019-02-14 17:04:00-05:00,SGEN,negative
1128369.0,Seattle Genetics Receives $30M Milestone Payment From Takeda For European Commission Approval of ADCETRIS,2019-02-11 08:01:00-05:00,SGEN,positive
1128370.0,66 Biggest Movers From Friday,2019-02-11 04:33:00-05:00,SGEN,neutral
1128371.0,48 Stocks Moving In Friday's Mid-Day Session,2019-02-08 12:42:00-05:00,SGEN,neutral
1128372.0,Seattle Genetics shares are trading lower after the company reported Q4 EPS of $(0.75) missing the $(0.43) estimate.,2019-02-08 12:06:00-05:00,SGEN,negative
1128373.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,SGEN,negative
1128374.0,Seattle Genetics Sees FY19 ADCETRIS Net Product Sales $610M-$640M,2019-02-07 16:06:00-05:00,SGEN,neutral
1128375.0,"Seattle Genetics Q4 GAAP EPS $(0.75) May Not Compare $(0.43) Estimate, Sales $174.513M Beat $163.71M Estimate",2019-02-07 16:04:00-05:00,SGEN,neutral
1128376.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,SGEN,neutral
1128377.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,SGEN,neutral
1128378.0,"Seattle Genetics, Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas at ASH 2018",2018-12-04 04:48:00-05:00,SGEN,positive
1128379.0,Seattle Genetics Announces Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS in Newly Diagnosed Advanced Hodgkin Lymphoma Presented at ASH 2018  Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD vs ABVD,2018-12-02 20:03:00-05:00,SGEN,positive
1128380.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,SGEN,neutral
1128381.0,55 Biggest Movers From Friday,2018-11-19 05:53:00-05:00,SGEN,neutral
1128382.0,48 Stocks Moving In Friday's Mid-Day Session,2018-11-16 13:15:00-05:00,SGEN,neutral
1128383.0,Shares of Seattle Genetics are trading higher by 4.68% after the FDA approved Adcetris.,2018-11-16 12:03:00-05:00,SGEN,positive
1128384.0,FDA Grants Approval Of Adcetris To Seattle Genetics,2018-11-16 10:45:00-05:00,SGEN,positive
1128385.0,Seattle Genetics Reports FDA Has Granted Breakthrough Therapy Designation To ADCETRIS For Frontline Peripheral T-Cell Lymphomas; Designation Based On Positive Phase 3 ECHELON-2 Trial,2018-11-15 08:12:00-05:00,SGEN,positive
1128386.0,Seattle Genetics Reports FDA Granted Breakthrough Therapy Designation For ADCETRIS For Frontline Peripheral T-Cell Lymphomas,2018-11-15 08:02:00-05:00,SGEN,positive
1128387.0,"Seattle Genetics Reports Initiation Of Phase 1 Trial Of SEA-BCMA For Patients With Relapse, Refractory Multiple Myeloma",2018-11-14 08:04:00-05:00,SGEN,neutral
1128388.0,Seattle Genetics Submits a Supplemental Biologics License Application for ADCETRIS to the FDA,2018-11-05 08:10:00-05:00,SGEN,neutral
1128389.0,Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS Development Program On Dec 3,2018-11-01 17:30:00-04:00,SGEN,positive
1128390.0,71 Biggest Movers From Friday,2018-10-29 05:33:00-04:00,SGEN,neutral
1128391.0,56 Stocks Moving In Friday's Mid-Day Session,2018-10-26 12:49:00-04:00,SGEN,neutral
1128392.0,Seattle Genetics shares are trading down 18.3% after the company missed Q3 EPS estimates.,2018-10-26 09:41:00-04:00,SGEN,neutral
1128393.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,SGEN,negative
1128394.0,"Seattle Genetics Highlights Encore, Added Analyses From Phase 3 ECHELON-1 Trial For ADCETRIS In Combo With Chemotherapy In Frontline Advanced HL",2018-10-26 08:08:00-04:00,SGEN,positive
1128395.0,"Seattle Genetics, Inc. Q3 EPS $(0.42) Misses $(0.27) Estimate, Sales $169.4M Beat $166.92M Estimate",2018-10-25 16:04:00-04:00,SGEN,negative
1128396.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,SGEN,negative
1128397.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,SGEN,neutral
1128398.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,SGEN,neutral
1128399.0,23 Stocks Moving In Friday's Pre-Market Session,2018-10-05 08:09:00-04:00,SGEN,neutral
1128400.0,"Stocks Which Set New 52-Week High Yesterday, October 3rd",2018-10-04 11:18:00-04:00,SGEN,neutral
1128401.0,"Stocks Which Set New 52-Week High Yesterday, October 2nd",2018-10-03 12:59:00-04:00,SGEN,neutral
1128402.0,10 Biggest Price Target Changes For Wednesday,2018-10-03 09:51:00-04:00,SGEN,neutral
1128403.0,"Barclays Maintains Overweight on Seattle Genetics, Raises Price Target to $95",2018-10-03 08:05:00-04:00,SGEN,negative
1128404.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,SGEN,neutral
1128405.0,A Peek Into The Markets: US Stock Futures Up; Dow Futures Rise Over 200 Points,2018-10-01 06:59:00-04:00,SGEN,neutral
1128406.0,Seattle Genetics and Takeda Announces its Phase 3 ECHELON-2 Clinical Trial of ADCETRIS Met its Primary Endpoint,2018-10-01 06:48:00-04:00,SGEN,neutral
1128407.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,SGEN,neutral
1128408.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,SGEN,neutral
1128409.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,SGEN,positive
1128410.0,"Leerink Swann Initiates Coverage On Seattle Genetics with Outperform Rating, Announces $101 Price Target",2018-09-25 08:53:00-04:00,SGEN,neutral
1128411.0,"Stocks Which Set New 52-Week High Friday, September 21",2018-09-24 09:43:00-04:00,SGEN,neutral
1128412.0,"Seattle Genetics Announces ADCETRIS Approval in Japan for Frontline Hodgkin Lymphoma, Approval Triggers Milestone Payment to Seattle Genetics of $10 Million",2018-09-21 10:49:00-04:00,SGEN,positive
1128413.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,SGEN,negative
1128414.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,SGEN,neutral
1128415.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,SGEN,neutral
1128416.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,SGEN,positive
1128417.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,SGEN,neutral
1128418.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,SGEN,neutral
1128419.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,SGEN,neutral
1128420.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,SGEN,positive
1128421.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,SGEN,neutral
1128422.0,Form 4 Filing Late Thursday Showed Seattle Genetics CEO Clay Siegall Sold 25K Shares at $74.95,2018-08-24 10:24:00-04:00,SGEN,positive
1128423.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,SGEN,negative
1128424.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,SGEN,neutral
1128425.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,SGEN,negative
1128426.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,SGEN,neutral
1128427.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,SGEN,neutral
1128428.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,SGEN,neutral
1128429.0,Form 4 Filing Late Thursday Showed Seattle Genetics Director Marc Lippman Sold 7.4K Shares At $69.25,2018-08-03 11:30:00-04:00,SGEN,positive
1128430.0,"Stocks Which Set New 52-Week High Friday, July 27th",2018-07-30 12:05:00-04:00,SGEN,neutral
1128431.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,SGEN,neutral
1128432.0,Seattle Genetics Sees Q3 Sales Of ADCETRIS To Be In Range Of $130-$135M,2018-07-26 16:05:00-04:00,SGEN,neutral
1128433.0,"Seattle Genetics Q2 EPS $0.47 Beats $(0.39) Estimate, Sales $170.173M Beat $141.07M Estimate",2018-07-26 16:05:00-04:00,SGEN,neutral
1128434.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,SGEN,neutral
1128435.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,SGEN,negative
1128436.0,Earnings Preview For Seattle Genetics,2018-07-26 08:20:00-04:00,SGEN,neutral
1128437.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,SGEN,neutral
1128438.0,"UPDATE: RBC On Seattle Genetics Highlights Adcetris Trial Halt Was Strictly Administrative, Sees No Safety Concern",2018-07-17 13:00:00-04:00,SGEN,positive
1128439.0,"RBC Capital Comments On Seattle Genetics Midday, Says Is 'Not Conncerned' By Report Of Halt Of NCI-Sponsored Trial Of Adcetris In HIV-Associated Hodgkin's Lymphoma",2018-07-17 12:59:00-04:00,SGEN,neutral
1128440.0,"Seattle Genetics Shares Trading Lower As Traders Circulate Document That Shows Brentuximab Enrollment Was Halted, Issued Warning Letter",2018-07-17 09:51:00-04:00,SGEN,negative
1128441.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,SGEN,neutral
1128442.0,"Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors, Trial to Inform Broader Development Program Strategy",2018-07-12 08:04:00-04:00,SGEN,positive
1128443.0,"Jim Cramer Shares His Thoughts On Cisco, Roku, Under Armour And More",2018-07-12 07:31:00-04:00,SGEN,positive
1128444.0,tle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer,2018-07-11 08:06:00-04:00,SGEN,negative
1128445.0,Seattle Genetics Reports Initial Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer,2018-06-13 08:06:00-04:00,SGEN,negative
1128446.0,10 Biggest Price Target Changes For Monday,2018-06-11 10:00:00-04:00,SGEN,neutral
1128447.0,"Benzinga's Top Upgrades, Downgrades For June 11, 2018",2018-06-11 09:22:00-04:00,SGEN,positive
1128448.0,"SunTrust Robinson Humphrey Upgrades Seattle Genetics to Buy, Raises Price Target to $80",2018-06-11 07:52:00-04:00,SGEN,neutral
1128449.0,"Immunomedics Amended 13D Filing From Seattle Genetics Shows Reduced Stake From ~11.66M Shares To ~8.28M Shares, Or 4.9% Stake",2018-06-05 16:29:00-04:00,SGEN,positive
1128450.0,UPDATE: Seattle Genetics Says Results From Patients Treated in North America Demonstrate 2-Year Modified Progression-Free Survival of 84.3% in the ADCETRIS Combination Arm Compared to 73.7% in the ABVD Arm,2018-06-04 09:05:00-04:00,SGEN,neutral
1128451.0,Seattle Genetics Reports Added Analyses From Phase 3 ECHELON-1 Trial Of ADCETRIS In Newly-Diagnosed Advanced Hodgkin Lymphoma At ASCO: Data Continues To Support Superior Clinical Activity Of ADCETRIS In Combo vs ABVD In Frontline Advanced Hodgkin Lymphoma,2018-06-04 09:05:00-04:00,SGEN,positive
1128452.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,SGEN,negative
1128453.0,"Seattle Genetics, Astellas Present on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy at #ASCO2018",2018-06-03 19:17:00-04:00,SGEN,negative
1128454.0,13D/A Filing Late Wednesday Showed Baker Bros Raised Stake In Seattle Genetics From ~45.723M shares to ~50.693M or 32.1%,2018-05-03 10:15:00-04:00,SGEN,positive
1128455.0,Seattle Genetics Shares Up 7.6% After Co. Thursday Reported Mixed Q1 Results,2018-04-27 12:09:00-04:00,SGEN,positive
1128456.0,"Seattle Genetics Q1 EPS $(0.73) Misses $(0.42) Est., Sales $140.6M Beats $119.06M Est.",2018-04-26 16:02:00-04:00,SGEN,negative
1128457.0,"Biotech Stock Roundup: Protagonist Therapeutics, Verona, Amgen And More",2018-03-29 11:28:00-04:00,SGEN,neutral
1128458.0,"Seattle Genetics, Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer",2018-03-26 08:04:00-04:00,SGEN,negative
1128459.0,Seattle Genetics Announces FDA Approval of ADCETRIS In Combination With Chemo For Adults With Previously Untreated Stage III or IV Classical Hodgkin Lymphoma,2018-03-20 12:49:00-04:00,SGEN,positive
1128460.0,Seattle Genetics Begins New Phase 1 Study in Relapsed or Refractory Multiple Myeloma,2018-03-07 08:00:00-05:00,SGEN,neutral
1128461.0,Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period With Respect To Proposed Acquisition Of Cascadian Therapeutics,2018-02-16 08:00:00-05:00,SGEN,positive
1128462.0,"JP Morgan Maintains Neutral on Seattle Genetics, Raises price target to $66.00",2018-02-14 08:24:00-05:00,SGEN,positive
1128463.0,JP Morgan Upgrades Seattle Genetics to Overweight,2018-02-14 08:19:00-05:00,SGEN,neutral
1128464.0,Seattle Genetics Reports Multi-Program Immuno-Oncology Collaboration Deal With Pieris Pharma,2018-02-09 06:45:00-05:00,SGEN,neutral
1128465.0,Seattle Genetics Commences Previously Announced Tender Offer for Cascadian Therapeutics at $10/Share,2018-02-08 17:45:00-05:00,SGEN,neutral
1128466.0,Seattle Genetics Sees FY18 Sales $470-$505M vs $575M Est.,2018-02-06 16:04:00-05:00,SGEN,neutral
1128467.0,"Seattle Genetics Reports Q4 EPS $(0.41) vs $(0.43) Est., Sales $129.6M vs $116M Est.",2018-02-06 16:03:00-05:00,SGEN,neutral
1128468.0,Benzinga Pro's 6 Stocks To Watch Today,2018-01-31 08:42:00-05:00,SGEN,neutral
1128469.0,Seattle Genetics Announces a $550M Offering Following the $614M Acquisition of Cascadian Therapeutics,2018-01-31 06:42:00-05:00,SGEN,neutral
1128470.0,"Cascadian Therapeutics to be Acquired by Seattle Genetics for $10/Share Cash, Shares of Cascadian Closed at $5.90/Share Tuesday",2018-01-31 06:31:00-05:00,SGEN,positive
1128471.0,Seattle Genetics' Adcetris Gets EU Nod For Label Expansion,2018-01-23 11:14:00-05:00,SGEN,neutral
1128472.0,Seattle Genetics Announces ADCETRIS Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy,2018-01-22 08:17:00-05:00,SGEN,positive
1128473.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,SGEN,positive
1128474.0,FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS in Frontline Advanced Hodgkin Lymphoma,2018-01-02 08:02:00-05:00,SGEN,positive
1128475.0,42 Biggest Movers From Yesterday,2017-12-12 05:56:00-05:00,SGEN,neutral
1128476.0,30 Stocks Moving In Monday's Mid-Day Session,2017-12-11 12:07:00-05:00,SGEN,neutral
1128477.0,"Takeda, Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma at #ASH2017",2017-12-10 16:24:00-05:00,SGEN,positive
1128478.0,Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS in Frontline Mature T-Cell Lymphoma at #ASH2017,2017-12-10 15:21:00-05:00,SGEN,positive
1128479.0,"Seattle Genetics Says Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS in CD30-Expressing Cutaneous T-Cell Lymphoma at #ASH2017 Indicate Primary, Secondary Endpoints per Investigator Better than Previously Reported",2017-12-09 14:44:00-05:00,SGEN,positive
1128480.0,Seattle Genetics Gives Updated Phase 1 Data for Ladiratuzumab Vedotin,2017-12-07 08:04:00-05:00,SGEN,neutral
1128481.0,Seattle Genetics Announces FDA Approval of ADCETRIS,2017-11-09 12:40:00-05:00,SGEN,positive
1128482.0,"Seattle Genetics, Astellas Pharma Reports Initiation Of Phase 1b Trial Of Enfortumaba Vedotin In Combo With Immune Checkpoint Inhibitor Therapeies In Locally Advanced, Metastatic Urothelial Cancer: 'ADC Combination Study Focuses on First-Line Treatment'",2017-11-08 08:02:00-05:00,SGEN,negative
1128483.0,Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma,2017-11-02 08:09:00-04:00,SGEN,positive
1128484.0,Bank of America Upgrades Seattle Genetics to Neutral,2017-10-27 09:22:00-04:00,SGEN,neutral
1128485.0,"Seattle Genetics Raises FY17 Outlook: License Revenue From $75M-$90M to $90M-$100M, Royalty Sales From $50M-$55M to $60M-$65M",2017-10-26 16:15:00-04:00,SGEN,neutral
1128486.0,"Seattle Genetics Reports EPS $0.34  vs $(0.23) In Same Qtr. Last Year, Sales $135.3M vs $112.81M Est.",2017-10-26 16:14:00-04:00,SGEN,neutral
1128487.0,The Market In 5 Minutes: Tax Overhaul In Focus As Senate Passes Budget Plan,2017-10-20 09:11:00-04:00,SGEN,neutral
1128488.0,"Benzinga's Top Upgrades, Downgrades For October 20, 2017",2017-10-20 09:04:00-04:00,SGEN,positive
1128489.0,Barclays Upgrades Seattle Genetics to Overweight,2017-10-20 06:31:00-04:00,SGEN,negative
1128490.0,Seattle Genetics Announces 2 Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer,2017-10-11 08:02:00-04:00,SGEN,negative
1128491.0,Seattle Genetics Reports Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer,2017-10-11 08:01:00-04:00,SGEN,negative
1128492.0,"Seattle Genetics, Astellas Pharma Report Initiation Of Pivotal Trial Of Enfortumab Vedotin For Patients With Locally Advanced, Metastatic Urothelial Cancer",2017-10-10 08:10:00-04:00,SGEN,negative
1128493.0,"Jim Cramer Advises His Viewers On Teva, AT&T And More",2017-10-05 07:51:00-04:00,SGEN,neutral
1128494.0,"UPDATE: Seattle Genetics Says 'In the 66% of Patients who Achieved Complete Remission, Both Median Overall Survival and Progression-Free Survival Not Yet Reached'",2017-10-03 08:12:00-04:00,SGEN,negative
1128495.0,"Seattle Genetics, Takeda Highlight Publication 'Blood' Final Long-Term Survival Data From ADCETRIS Phase 2 Trial: 'Estimated 5-Year Overall Survival Rate 60%, 5-Year Progression-Free Survival Rate 39%'",2017-10-03 08:12:00-04:00,SGEN,positive
1128496.0,20 Biggest Mid-Day Gainers For Monday,2017-10-02 12:04:00-04:00,SGEN,neutral
1128497.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,SGEN,neutral
1128498.0,"A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Manufacturing, Construction Spending Data",2017-10-02 07:13:00-04:00,SGEN,positive
1128499.0,Seattle Genetics Reports Received FDA Breakthrough Therapy Designation For ADCETRIS In Frontline Advanced Hodgkin Lymphoma,2017-10-02 06:49:00-04:00,SGEN,positive
1128500.0,Benzinga's Option Alert Recap From September 19,2017-09-19 16:30:00-04:00,SGEN,positive
1128501.0,Seattle Genetics Option Alert: Oct 20 $50 Puts Sweep (33) at the Bid: 578 @ $1.005 vs 555 OI; Ref=$52.534,2017-09-19 09:48:00-04:00,SGEN,positive
1128502.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,SGEN,neutral
1128503.0,RBC Initiates Coverage on 6 Pharma Stocks After Hours,2017-09-14 16:47:00-04:00,SGEN,neutral
1128504.0,"Morgan Stanley Healthcare Conference Continues Today, Presenters Include: Innoviva, Seattle Genetics, Lab Corp, Anthem, Juno Therapeutics, and Intercept Pharmaceuticals",2017-09-12 08:58:00-04:00,SGEN,neutral
1128505.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,SGEN,neutral
1128506.0,Seattle Genetics Exercises its Option to Co-Develop Tisotumab Vedotin with Genmab,2017-08-29 06:54:00-04:00,SGEN,neutral
1128507.0,"Seattle Genetics Reports FDA Accepted Supplemental BLA, Grants Priority Review For ADCETRIS In Cutaneous T-Cell Lymphoma",2017-08-16 08:01:00-04:00,SGEN,positive
1128508.0,Seattle Genetics Buys Bothell Manufacturing Facility From Bristol-Myers Squibb,2017-08-01 16:01:00-04:00,SGEN,neutral
1128509.0,"Seattle Genetics Reports Q2 EPS $(0.39) vs $(0.42) Est., Sales $108.2M vs $108.8M Est.",2017-07-27 16:14:00-04:00,SGEN,neutral
1128510.0,Seattle Genetics Reports Clinical Collaboration To Expand Therapeutic Evaluation Of SGN-LIV1A In Triple Negative Breast Cancer,2017-07-24 08:15:00-04:00,SGEN,negative
1128512.0,12 Biggest Mid-Day Losers For Monday,2017-06-26 13:09:00-04:00,SGEN,negative
1128513.0,"PiperJaffray Out On Seattle Genetics, Says ECHELON-1 Data Likely Good Enough To Warrand ADCETRIS Approval, Maintains Neutral Rating",2017-06-26 09:59:00-04:00,SGEN,positive
1128514.0,"Adam Feuerstein Tweets: $SGEN - in ECHELON, Adcetris PFS improvement over standard of care is just under 5 percentage points. That's not spectacular.",2017-06-26 06:57:00-04:00,SGEN,positive
1128515.0,Seattle Genetics Announces Phase 3 ECHELON-1 Trial Met its Primary Endpoint,2017-06-26 06:47:00-04:00,SGEN,neutral
1128519.0,Seattle Genetics Reports Submission Of BLA For ADCETRIS In Cutaneous T-Cell Lymphoma,2017-06-20 08:03:00-04:00,SGEN,neutral
1128520.0,10 Biggest Mid-Day Losers For Monday,2017-06-19 12:45:00-04:00,SGEN,negative
1128522.0,Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For $6.7B,2017-06-19 10:11:00-04:00,SGEN,positive
1128523.0,15 Stocks Moving In Monday's Pre-Market Session,2017-06-19 08:37:00-04:00,SGEN,neutral
1128524.0,"Seattle Genetics Discontinues Phase 3 CASCADE Trial in Frontline Acute Myeloid Leukemia, Data Showed a Higher Rate of Deaths",2017-06-19 06:46:00-04:00,SGEN,neutral
1128525.0,"UPDATE: Seattle Genetics, Bristol-Myers Reports Combo Data Show 85% Objective Response Rate, 63% Complete Response Rate with an Acceptable Safety Profile",2017-06-15 07:02:00-04:00,SGEN,positive
1128526.0,"Seattle Genetics, Bristol-Myers Reports Interim Phase 1/2 Data Evaluating Combo Of ADCETRIS, Opdivo In Relapsed Hodgkin Lymphoma",2017-06-15 07:01:00-04:00,SGEN,neutral
1128527.0,Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS and OPDIVO,2017-06-15 06:58:00-04:00,SGEN,positive
1128528.0,Takeda and Seattle Genetics Reports Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS,2017-06-07 08:05:00-04:00,SGEN,neutral
1128529.0,Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo and ADCETRIS in Phase 3 Trial,2017-06-02 06:06:00-04:00,SGEN,positive
1128530.0,"Companies Holding Shareholder Meetings Today Include: Mattel, Aetna, Yum! Brands, Seattle Genetics, Rosetta Stone, CBS, & Amgen",2017-05-19 09:00:00-04:00,SGEN,neutral
1128531.0,"Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics",2017-05-16 08:32:00-04:00,SGEN,positive
1128532.0,Immunomedics Announces Mutual Deal with Seattle Genetics for Dissolving of Previously-Agreed Upon Exclusive Global Licensing Deal,2017-05-05 08:49:00-04:00,SGEN,positive
1128533.0,Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan,2017-05-05 08:07:00-04:00,SGEN,positive
1128534.0,"Seattle Genetics Reports Q1 EPS $(0.42) In-line With Est., Sales $109.1M vs $103.23M Est.",2017-04-27 16:02:00-04:00,SGEN,neutral
1128535.0,Oppenheimer Initiates Coverage On Seattle Genetics With Perform,2017-03-16 09:23:00-04:00,SGEN,neutral
1128536.0,"Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers",2017-03-15 08:25:00-04:00,SGEN,neutral
1128537.0,"8-K from Seattle Genetics Shows Delaware Court of Chancery Issued Temporary Restraining Order Enjoining Taking Any Action in Furthering of Closing of Deal between Co., Immunomedics Related to IMMU-132",2017-03-10 07:38:00-05:00,SGEN,neutral
1128538.0,"Cowen Annual Healthcare Conference Concludes Today; Presenters Include Agilent Tech, Incyte, GW Pharma, Teva Pharma, NantKwest, Seattle Genetics, And Celgene",2017-03-08 08:25:00-05:00,SGEN,neutral
1128539.0,FDA Lifts Clinical Hold on Seattle Genetics' Phase 1 Trials of Vadastuximab Talirine,2017-03-06 06:45:00-05:00,SGEN,neutral
1128540.0,Immunomedics Says Co. Will Promptly Seek RRelief In Proceeding In Delaware Chancery Court While Co.. Continues To Take Steps To Protect Rights Of All Stockholders,2017-03-03 10:22:00-05:00,SGEN,positive
1128541.0,Immunomedics Issues Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation,2017-02-27 08:02:00-05:00,SGEN,positive
1128542.0,"Immunomedics' Shareholder venBio Select Advisor Issues Statement In Opposition To Recent Partnership With Seattle Genetics, Files Motion For Injunction",2017-02-14 11:52:00-05:00,SGEN,neutral
1128543.0,Shkreli: I'd Short Immunomedics On The Bounce,2017-02-10 16:08:00-05:00,SGEN,neutral
1128544.0,Seattle Genetics Shares Higher Following Big Volume Spike,2017-02-10 14:17:00-05:00,SGEN,positive
1128545.0,Mid-Day Market Update: Infinera Surges On Earnings Beat; ChannelAdvisor Shares Plunge,2017-02-10 12:27:00-05:00,SGEN,positive
1128546.0,Bank of America Downgrades Seattle Genetics To Underperform,2017-02-10 09:26:00-05:00,SGEN,neutral
1128547.0,"Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive $250M Upfront, Sell $15M of Stock to Seattle Genetics",2017-02-10 06:55:00-05:00,SGEN,positive
1128548.0,Seattle Genetics Sees FY17 Sales $405M-$445M,2017-02-09 16:15:00-05:00,SGEN,neutral
1128549.0,"Seattle Genetics Reports Q4 EPS $(0.39) vs $(0.34) Est., Sales $105.3M vs $105M Est.",2017-02-09 16:14:00-05:00,SGEN,neutral
1128550.0,Seattle Genetics Shares Unaffected Premarket as FDA Site Shows Brentuximab Vedotin Designated for Orphan Drug Status,2017-02-08 07:00:00-05:00,SGEN,positive
1128551.0,"TheStreet's Adam Feuerstein Tweets '$SGEN spox says Adcetris-Opdivo study halt is ""purely procedural. Trial is going well. We are amending protocol to add additional patients.'",2017-01-05 12:22:00-05:00,SGEN,positive
1128552.0,"Seattle Genetics, Bristol-Myers Study of Opdivo and Adcetris Combo Halted Pending Protocol Amendment To Allow Additional Patients TO Be Enrolled and Treated To Further Characterize Safety And Efficacy",2017-01-05 11:27:00-05:00,SGEN,positive
1128553.0,"Seattle Genetics Shares Move to Session Lows as Hearing Enrollment Suspended for Adcetris, Opdivo Combo",2017-01-05 11:23:00-05:00,SGEN,negative
1128554.0,Seattle Genetics Begins Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma,2017-01-05 08:02:00-05:00,SGEN,neutral
1128555.0,4 Big Biotech Losers Heading Into The New Year,2016-12-30 10:46:00-05:00,SGEN,negative
1128556.0,2 Reasons Seattle Genetics' Clinical Holds Were A Surprise,2016-12-28 10:16:00-05:00,SGEN,positive
1128557.0,5 Stocks You Should Be Watching Today,2016-12-28 05:40:00-05:00,SGEN,neutral
1128558.0,Mid-Afternoon Market Update: Ionis Pharma Rises After FDA Approval Of Spinraza; Seattle Genetics Shares Plummet,2016-12-27 14:30:00-05:00,SGEN,positive
1128559.0,10 Biggest Mid-Day Losers For Tuesday,2016-12-27 12:55:00-05:00,SGEN,negative
1128560.0,"Credit Suisse Says Seattle Genetics Surprise Clinical Hold Increases Risk To AML Programs, Decreases PT From $70 To $60",2016-12-27 12:43:00-05:00,SGEN,positive
1128561.0,Mid-Day Market Update: Crude Oil Up Over 1%; Endologix Shares Slide,2016-12-27 12:17:00-05:00,SGEN,negative
1128562.0,Seattle Genetics - No Bounce After Phase 1 Trial Put On Clinical Hold,2016-12-27 11:34:00-05:00,SGEN,negative
1128563.0,Mid-Morning Market Update: Markets Open Higher; Groupe Casino Offers To Buy Cnova,2016-12-27 10:03:00-05:00,SGEN,neutral
1128564.0,"Seattle Genetics Resumes Trade, Now Down 13.9%",2016-12-27 08:36:00-05:00,SGEN,neutral
1128565.0,Seattle Genetics To Resume At 8:30am ET,2016-12-27 08:06:00-05:00,SGEN,neutral
1128566.0,UPDATE: Holds On Vadastuximab Talirine To Evaluate Risk Of Hepatotoxicity In Patients With SGN-CD33A,2016-12-27 08:01:00-05:00,SGEN,negative
1128567.0,Seattle Genetics Reports Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine,2016-12-27 08:00:00-05:00,SGEN,neutral
1128568.0,Seattle Genetics Halted News Pending,2016-12-27 08:00:00-05:00,SGEN,neutral
1128569.0,10 Stocks With Lowest Close In Three Weeks,2016-12-13 06:45:00-05:00,SGEN,negative
1128570.0,8 Biggest Price Target Changes For Monday,2016-12-12 09:24:00-05:00,SGEN,neutral
1128571.0,"Credit Suisse Downgrades Seattle Genetics to Neutral, Raises Target to $70.00",2016-12-12 07:15:00-05:00,SGEN,positive
1128572.0,Biotech Winners And Losers From ASH Conference,2016-12-09 11:59:00-05:00,SGEN,negative
1128573.0,8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting,2016-12-06 16:09:00-05:00,SGEN,neutral
1128574.0,UPDATE: Seattle Genetics Says 'Phase 1 Trial of ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Shows Four-Year Survival Rate of 80%',2016-12-05 13:01:00-05:00,SGEN,positive
1128575.0,Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS in T-Cell Lymphomas: Data Support Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas,2016-12-05 13:01:00-05:00,SGEN,positive
1128576.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,SGEN,positive
1128577.0,"Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Says Data Supportive Of Phase 3 CASCADE Study",2016-12-05 10:00:00-05:00,SGEN,positive
1128578.0,"Takeda, Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma at ASH 2016",2016-12-03 18:56:00-05:00,SGEN,positive
1128579.0,Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS in Frontline Diffuse Large B-cell Lymphoma at ASH 2016,2016-12-03 14:40:00-05:00,SGEN,neutral
1128580.0,"Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion",2016-11-29 10:39:00-05:00,SGEN,neutral
1128581.0,Barclays Downgrades Seattle Genetics to Equal-Weight,2016-11-29 05:57:00-05:00,SGEN,neutral
1128582.0,Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma,2016-11-10 08:12:00-05:00,SGEN,neutral
1128583.0,Stocks Hitting 52-Week Highs,2016-11-09 10:17:00-05:00,SGEN,neutral
1128584.0,"10 Stocks That Rallied Four Days, Then Sold Off On Friday",2016-11-07 07:00:00-05:00,SGEN,neutral
1128585.0,10 Stocks That Rallied Three Days On No News,2016-11-03 06:03:00-04:00,SGEN,negative
1128586.0,"Seattle Genetics Reports Q3 EPS $(0.23) vs. Est. $(0.29), Rev. $106.3M vs. Est. $101.7M",2016-10-27 16:58:00-04:00,SGEN,neutral
1128587.0,Seattle Genetics Shows Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS Data Presentations at ISHL 2016,2016-10-20 08:02:00-04:00,SGEN,positive
1128588.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-17 08:46:00-04:00,SGEN,neutral
1128589.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-13 08:48:00-04:00,SGEN,neutral
1128590.0,Seattle Genetics Names Dr. Vaughn Himes Chief Technical Officer,2016-10-04 08:01:00-04:00,SGEN,neutral
1128591.0,Seattle Genetics Initiates Phase 1 SGN Trial,2016-09-19 08:06:00-04:00,SGEN,neutral
1128592.0,"Seattle Genetics Reports Initiation of Phase 1 Trial of SGN-CD123A for Patients with Relapses, Refractory Acute Myeloid Leukemia",2016-09-19 08:02:00-04:00,SGEN,neutral
1128593.0,7 Biggest Price Target Changes For Thursday,2016-09-15 10:07:00-04:00,SGEN,neutral
1128594.0,Seattle Genetics No Longer On Goldman Sachs' Sell List,2016-09-15 09:48:00-04:00,SGEN,negative
1128595.0,Benzinga's Top Upgrades,2016-09-15 09:04:00-04:00,SGEN,positive
1128596.0,The Market In 5 Minutes: Apple Helps Lead Stocks Higher,2016-09-15 08:58:00-04:00,SGEN,positive
1128597.0,"Goldman Sachs Upgrades Seattle Genetics to Neutral, Raises PT to $47.00, Removed From Americas Sell List",2016-09-15 06:02:00-04:00,SGEN,neutral
1128598.0,Stocks Hitting 52-Week Highs,2016-09-14 10:10:00-04:00,SGEN,neutral
1128599.0,Stocks Hitting 52-Week Highs,2016-09-09 11:10:00-04:00,SGEN,neutral
1128600.0,Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product,2016-09-07 10:50:00-04:00,SGEN,neutral
1128601.0,Benzinga's Top Initiations,2016-09-07 09:29:00-04:00,SGEN,positive
1128602.0,"Morgan Stanley Initiates Coverage on Seattle Genetics at Overweight, Announces $60.00 PT",2016-09-07 06:21:00-04:00,SGEN,negative
1128603.0,"Takeda, Seattle Genetics Report Data from Phase 3 ALCANZA Trial of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma: Met  Primary Endpoint, Showed Highly Statistically Significant Improvement",2016-08-01 07:00:00-04:00,SGEN,positive
1128604.0,Seattle Genetics Downgraded To Hold At Cantor Fitzgerald,2016-07-27 08:37:00-04:00,SGEN,neutral
1128605.0,"Seattle Genetics Reports Q2 Loss -$0.23 vs Est Loss Of -$0.32, Rev $95.4M vs $94.14M Est",2016-07-26 17:04:00-04:00,SGEN,negative
1128606.0,"Incyte, Seattle Genetics Seen as Possible Acquisition Targets for their Cancer Treatments -Reuters",2016-07-19 04:52:00-04:00,SGEN,negative
1128607.0,"UPDATE: Seattle, Takeda Report 'Patients Who Achieved a Complete Remission Had Estimated Five-Year Overall Survival of 64%, Five-Year Progression-Free Survival of 52%'",2016-07-18 10:03:00-04:00,SGEN,neutral
1128608.0,"UPDATE: Seattle Genetics, Takeda Report 'Estimated Five-Year Overall Survival Rate 41%, Five-Year Progression-Free Survival Rate 22%",2016-07-18 10:02:00-04:00,SGEN,neutral
1128609.0,"Seattle Genetics, Takeda Pharma Report Publication of Final Data from ADCETRIS Phase 2 Trial",2016-07-18 10:01:00-04:00,SGEN,neutral
1128610.0,Seattle Genetics Reports EC Approves ADCETRIS for Treatment of Post-Transplant Hodgkin Lymphoma,2016-07-06 08:02:00-04:00,SGEN,positive
1128611.0,"Seattle Genetics Announces Vadastuximab Talirine Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 41% Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 3A Combination Therapy",2016-06-11 08:42:00-04:00,SGEN,positive
1128612.0,Seattle Genetics Initiates Phase 3 Trial For Vadastuximab Talirine For Acute Myeloid Leukemia,2016-05-25 08:05:00-04:00,SGEN,neutral
1128613.0,"Seattle Genetics Reports Q1 EPS $(0.15) vs. Est. $(0.09), Rev. $111.2M vs. Est. $116M",2016-04-28 16:29:00-04:00,SGEN,neutral
1128614.0,"Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting",2016-04-18 08:01:00-04:00,SGEN,positive
1128615.0,"Baker Brothers Buys 502,523 Shares Of Seattle Genetics @$32.45/Share -Form 4",2016-03-08 17:10:00-05:00,SGEN,positive
1128616.0,The Most Notable Insider Buys And Sells Of Last Week,2016-03-07 16:53:00-05:00,SGEN,neutral
1128617.0,Benzinga's Top Initiations,2016-03-03 10:01:00-05:00,SGEN,positive
1128618.0,"SunTrust Robinson Humphrey Initiates Coverage on Seattle Genetics at Neutral, Announces $34.00 PT",2016-03-02 17:14:00-05:00,SGEN,neutral
1128619.0,3 Biotech Companies With Recent Large Insider Buying,2016-03-02 07:31:00-05:00,SGEN,neutral
1128620.0,Stocks To Watch During Cowen's 36th Annual Healthcare Conference,2016-03-01 13:21:00-05:00,SGEN,neutral
1128621.0,"Zillow, Prospect Capital Lead List Of Notable Insider Transactions Last Week",2016-02-29 15:14:00-05:00,SGEN,positive
1128622.0,10 Stocks Moving In Friday's After-Hours Session,2016-02-26 17:08:00-05:00,SGEN,neutral
1128623.0,Seattle Genetics Starts Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma,2016-02-25 08:00:00-05:00,SGEN,neutral
1128624.0,The 10 Most Notable Insider Transactions Last Week,2016-02-22 12:17:00-05:00,SGEN,neutral
1128625.0,Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (,2016-02-22 08:01:00-05:00,SGEN,neutral
1128626.0,"Cantor Upgrades Seattle Genetics To Buy, Firm Says Guidance Is Conservative",2016-02-10 11:27:00-05:00,SGEN,neutral
1128627.0,Benzinga's Top Upgrades,2016-02-10 08:55:00-05:00,SGEN,positive
1128628.0,Cantor Fitzgerald Upgrades Seattle Genetics to Buy,2016-02-10 07:37:00-05:00,SGEN,neutral
1128629.0,Seattle Genetics Sees FY16 Sales $390M-$430M vs $414M Est.,2016-02-09 16:04:00-05:00,SGEN,neutral
1128630.0,"Seattle Genetics Reports Q4 EPS $(0.18) vs $(0.20) Est., Sales $93.5M vs $88.3M Est.",2016-02-09 16:03:00-05:00,SGEN,neutral
1128631.0,Benzinga's Top Initiations,2016-02-04 09:56:00-05:00,SGEN,positive
1128632.0,"Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside",2016-02-04 09:15:00-05:00,SGEN,neutral
1128633.0,UPDATE: Seattle Genetics Says $20M Milestone Payment Triggered by Annual ADCETRIS Net Sales Exceeding $200M,2016-02-04 08:04:00-05:00,SGEN,neutral
1128634.0,"Seattle Genetics Reports Commercial, Regulatory Progress Under ADCETRIS Collab with Takeda",2016-02-04 08:03:00-05:00,SGEN,positive
1128635.0,"Barclays Initiates Coverage on Seattle Genetics at Overweight, Announces $51.00 PT",2016-02-04 04:02:00-05:00,SGEN,negative
1128636.0,"Credit Suisse Initiates Coverage on Seattle Genetics at Outperform, Announces $52.00 PT",2016-01-20 16:48:00-05:00,SGEN,positive
1128637.0,Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS in Combination with Opdivo in Relapsed or Refractory Non-Hodgkin Lymphoma,2015-12-23 08:01:00-05:00,SGEN,neutral
1128638.0,Seattle Genetics Shows Commitment to Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS Data Presentations at ASH 2015,2015-12-07 10:31:00-05:00,SGEN,positive
1128639.0,Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015,2015-12-06 08:42:00-05:00,SGEN,neutral
1128640.0,Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia,2015-11-23 08:00:00-05:00,SGEN,neutral
1128641.0,Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks,2015-11-18 11:05:00-05:00,SGEN,neutral
1128642.0,"Goldman Sachs Initiates Coverage on Seattle Genetics at Sell, Announces $33.00 PT",2015-11-18 06:49:00-05:00,SGEN,neutral
1128643.0,"Director Baker Buys 934,624 Shares of Seattle Genetics @$42.95/Share -Form 4",2015-11-10 20:07:00-05:00,SGEN,positive
1128644.0,Benzinga's Top Upgrades,2015-10-30 09:10:00-04:00,SGEN,positive
1128645.0,"Piper Jaffray Upgrades Seattle Genetics to Neutral, Raises PT to $44.00",2015-10-30 08:43:00-04:00,SGEN,neutral
1128646.0,Seattle Genetics Reports Q3 Loss of $0.21/Share vs Loss of $0.20/Share Est.,2015-10-29 16:02:00-04:00,SGEN,negative
1128647.0,"Seattle Genetics Reports Commencement of Phase 2 Trial of SGN-CD19A Combo Therapy in Relapsed, Refractory DLBCL",2015-10-29 08:08:00-04:00,SGEN,neutral
1128648.0,Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Previously Untreated Advanced Hodgkin Lymphoma,2015-10-27 08:01:00-04:00,SGEN,positive
1128649.0,Here's Why Biotechs Fell On Monday,2015-10-19 16:29:00-04:00,SGEN,neutral
1128650.0,Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),2015-10-19 08:00:00-04:00,SGEN,neutral
1128651.0,Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-line Hodgkin Lymphoma,2015-10-07 08:00:00-04:00,SGEN,neutral
1128652.0,"American Eagle Outfitters, Sears And Others That Insiders Have Been Buying",2015-09-23 08:42:00-04:00,SGEN,neutral
1128653.0,The Baker Brothers Are Bullish On Seattle Genetics And DBV Technologies,2015-09-16 15:51:00-04:00,SGEN,neutral
1128654.0,Amended 13D Filing from Baker Bros. on Seattle Genetics Shows 25.9% Stake,2015-09-15 17:39:00-04:00,SGEN,neutral
1128655.0,Seattle Genetics Announces Exercise of Over-Allotment Option; Gross Proceeds for ~13.46M Share Offering at $41/Share Totaled $552M,2015-09-14 08:10:00-04:00,SGEN,negative
1128656.0,Seattle Genetics Prices ~11.707M Share Offering of Common Stock @$41.00/Share,2015-09-10 19:16:00-04:00,SGEN,positive
1128657.0,"Seattle Genetics Announces Proposed Public Offering of Common Stock, $400M",2015-09-09 16:01:00-04:00,SGEN,neutral
1128658.0,Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL),2015-09-09 08:02:00-04:00,SGEN,neutral
1128659.0,A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month,2015-09-08 16:05:00-04:00,SGEN,negative
1128660.0,Sell Seattle Genetics' Latest Good News: Piper Jaffray,2015-08-18 10:27:00-04:00,SGEN,positive
1128661.0,Seattle Genetics Announces FDA Regular Approval of ADCETRIS  for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation,2015-08-17 16:08:00-04:00,SGEN,positive
1128662.0,"Seattle Genetics Reports Q2 EPS $(0.38) vs. Est. $(0.26), Rev. $77.096M vs. Est. $77.97M",2015-07-30 16:47:00-04:00,SGEN,neutral
1128663.0,"Seattle Genetics Begins Clinical Trial of ADCETRIS in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease",2015-07-09 09:01:00-04:00,SGEN,neutral
1128664.0,Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma,2015-06-17 09:01:00-04:00,SGEN,neutral
1128665.0,Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting,2015-06-01 10:47:00-04:00,SGEN,neutral
1128666.0,Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs,2015-05-28 09:02:00-04:00,SGEN,neutral
1128667.0,"Otonomy, Renren And Other Names To Watch Heading Into Next Week",2015-05-23 14:32:00-04:00,SGEN,neutral
1128668.0,"Williams-Sonoma, Salesforce.com, Deckers Outdoor Lead Wednesday's After-Hours Movers",2015-05-20 19:07:00-04:00,SGEN,neutral
1128669.0,Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks,2015-05-06 17:41:00-04:00,SGEN,positive
1128670.0,"Credit Suisse Assumes Seattle Genetics at Outperform, Announces $51.00 PT",2015-05-05 17:07:00-04:00,SGEN,positive
1128671.0,"Seattle Genetics Reports Q1 GAAP Loss of $0.17/Share vs Loss of $0.19/Share Est., Sales $82.2M vs $74M Est.",2015-04-30 16:12:00-04:00,SGEN,negative
1128672.0,"Seattle Genetics Announces FDA Acceptance of sBLA, Granting of Priority Review for ADCETRIS in AETHERA Setting, Sets Aug. 18, '15 as PDUFA Date",2015-04-20 09:01:00-04:00,SGEN,positive
1128673.0,Jefferies: 10 Buyout Targets To Own During The M&A Boom,2015-04-13 16:17:00-04:00,SGEN,neutral
1128674.0,"Kinder Morgan, Seattle Genetics And Others Insiders Have Been Buying",2015-03-16 10:48:00-04:00,SGEN,positive
1128675.0,"American Express, General Electric And Other Stocks Insiders Have Been Buying",2015-03-01 10:56:00-05:00,SGEN,neutral
1128676.0,Seattle Genetics Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial of ADCETRIS,2015-02-18 09:00:00-05:00,SGEN,neutral
1128677.0,Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-CD40 for Multiple Types of Advanced Solid Tumors,2015-02-17 09:09:00-05:00,SGEN,positive
1128678.0,Seattle Genetics Reports Advancement of Immuno-Oncology Program SEA-CD40 Into Phase 1 Trial for Advanced Solid Tumors,2015-02-17 09:03:00-05:00,SGEN,positive
1128679.0,Seattle Genetics Reports Q4 EPS of $(0.22) v $(0.25) Est,2015-02-10 16:13:00-05:00,SGEN,neutral
1128680.0,"Earnings Scheduled For February 10, 2015",2015-02-10 04:42:00-05:00,SGEN,neutral
1128681.0,"From Coca-Cola To Tesla, Here Are The 68 Most Important Earnings Expectations For The Week",2015-02-08 10:43:00-05:00,SGEN,positive
1128682.0,10 Biotech Stories You Might've Missed This Week,2015-01-15 13:18:00-05:00,SGEN,negative
1128683.0,Seattle Genetics Webcast Begins At JPMorgan Conference,2015-01-12 14:41:00-05:00,SGEN,neutral
1128684.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,SGEN,neutral
1128685.0,Seattle Genetics and Bristol Myers Announces Collaboration on Two Drugs,2015-01-12 08:02:00-05:00,SGEN,neutral
1128686.0,New Biotech ETF From ALPS,2015-01-02 08:05:00-05:00,SGEN,neutral
1128687.0,"Seattle Genetics Announces Initiation of Phase 1b Trial of SGN-CD33A in Combo with Frontline Standard of Care, as Consolidation Therpay for Acute Myeloid Leukemia",2014-12-18 09:01:00-05:00,SGEN,positive
1128688.0,"Amended 13D Filing from Baker Bros. Advisors on Seattle Genetics Shows Increased Stake from 20.27% as of Dec. 9th, 2014 to 22.6%",2014-12-17 17:21:00-05:00,SGEN,positive
1128689.0,"Seattle Genetics Director Baker Buys 1,247,896 Shares @$33.82/Share -Form 4",2014-12-10 20:08:00-05:00,SGEN,positive
1128690.0,Seattle Genetics Presents Phase 1 SGN-CD33A Data at ASH Annual Meeting,2014-12-08 19:36:00-05:00,SGEN,neutral
1128691.0,Seattle Genetics Presents Positive ADCETRIS Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting,2014-12-08 19:35:00-05:00,SGEN,positive
1128692.0,Seattle Genetics Highlights Multiple ADCETRIS Data Presentations In Frontline & Salvage Hodgkin Lymphoma At ASH Annual Meeting,2014-12-08 10:03:00-05:00,SGEN,neutral
1128693.0,"Seattle Genetics, Takeda Report Positive Phase 3 AETHERA Clinical Trial Data from ADCETRIS in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting",2014-12-06 12:36:00-05:00,SGEN,positive
1128694.0,Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting,2014-12-06 12:30:00-05:00,SGEN,neutral
1128695.0,5 Health Care Stocks Hurting From The Affordable Care Act,2014-11-04 20:46:00-05:00,SGEN,positive
1128696.0,"Cantor Fitzgerald Upgrades Seattle Genetics, Inc. to Hold, Raises PT to $35.00",2014-10-31 06:48:00-04:00,SGEN,neutral
1128697.0,"Seattle Genetics, Inc. Reports Q3 EPS of $(0.13) vs $(0.24) Est; Revenue of $75.90M vs $66.92M Est",2014-10-30 16:23:00-04:00,SGEN,neutral
1128698.0,Bank Of America Q3 Small & Mid-Cap Biotech Preview,2014-10-20 16:58:00-04:00,SGEN,neutral
1128699.0,Benzinga's Top Downgrades,2014-09-30 09:00:00-04:00,SGEN,positive
1128700.0,Bank of America Downgrades Seattle Genetics To Underperform,2014-09-30 08:38:00-04:00,SGEN,neutral
1128701.0,"UPDATE: Bank Of America Downgrades Seattle Genetics, Inc. On Frontline Expectations",2014-09-30 07:58:00-04:00,SGEN,neutral
1128702.0,"Seattle Genetics, Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS for Consolidation in Post-Transplant Hodgkin Lymphoma ",2014-09-29 06:53:00-04:00,SGEN,positive
1128703.0,"UPDATE: Seattle Genetics Shares Rise 8% After-Hours, Following Announcement of Monday Conference Call on ADCETRIS Phase 3 AETHERA Data",2014-09-26 19:06:00-04:00,SGEN,positive
1128704.0,"Seattle Genetics to to Discuss Top-line Data from ADCETRIS Phase 3 AETHERA Clinical Trial on September 29, 2014",2014-09-26 19:05:00-04:00,SGEN,neutral
1128705.0,"Seattle Genetics Offers Updated Progression-Free Survival, Overall Survival Data from ADCETRIS Frontline PTCL Phase 1 Trial",2014-09-24 09:01:00-04:00,SGEN,neutral
1128706.0,"UPDATE: Genmab Will Make Upfront Fee of $11M, Seattle Genetics Entitled to Get $200M+ in Possible Milestones",2014-09-10 08:06:00-04:00,SGEN,positive
1128707.0,"Genmab, Seattle Genetics Enter Into Antibody-Drug Conjugate Deal",2014-09-10 08:01:00-04:00,SGEN,neutral
1128708.0,Seattle Genetics Initiates Phase 1 Clinical Trial Of SGN-CD70A,2014-08-12 09:02:00-04:00,SGEN,neutral
1128709.0,"Seattle Genetics, Inc. Reports Q2 EPS of $(0.14) vs $(0.22) Est",2014-07-31 16:08:00-04:00,SGEN,neutral
1128710.0,UPDATE: UBS Upgrades Seattle Genetics,2014-07-09 11:44:00-04:00,SGEN,neutral
1128711.0,"UBS Upgrades Seattle Genetics, Inc. to Buy, Maintains $48.00 PT",2014-07-09 09:19:00-04:00,SGEN,neutral
1128712.0,Seattle Genetics Shares Fall 5%; May be Attributed to FDA Bulletin Date June 16: 'Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between January – March 2014',2014-06-17 09:46:00-04:00,SGEN,positive
1128713.0,Target And Others Insiders Have Been Buying,2014-06-08 14:30:00-04:00,SGEN,neutral
1128714.0,"Seattle Genetics Shareholder Baker Brothers Life Sciences Buys 281,963 Shares @$34.86/Share -Form 4",2014-06-04 19:35:00-04:00,SGEN,positive
1128715.0,Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD19A in Non-Hodgkin Lymphoma at ASCO 2014,2014-06-01 10:17:00-04:00,SGEN,neutral
1128716.0,Seattle Genetics Presents Data from Multiple Collaborator Antibody-Drug Conjugate Programs at ASCO ,2014-05-31 15:15:00-04:00,SGEN,neutral
1128717.0,Seattle Genetics To Present Antibody-Drug Conjugate At American Society of Clinical Oncology May 31-June 1,2014-05-14 17:17:00-04:00,SGEN,neutral
1128718.0,UPDATE: Bank Of America Upgrades Seattle Genetics,2014-05-06 09:31:00-04:00,SGEN,neutral
1128719.0,UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks,2014-05-06 09:06:00-04:00,SGEN,negative
1128720.0,Benzinga's Top Upgrades,2014-05-06 07:57:00-04:00,SGEN,positive
1128721.0,US Stock Futures Flat Ahead Of International Trade Data ,2014-05-06 07:29:00-04:00,SGEN,neutral
1128722.0,"Bank of America Upgrades Seattle Genetics, Inc. to Neutral, Lowers PO to $40.00",2014-05-06 06:57:00-04:00,SGEN,negative
1128723.0,"Seattle Genetics, Inc. Reports Q1 EPS of $(0.13) vs $(0.21) Est; Revenue of $68.30M vs $64.62M Est",2014-05-01 16:41:00-04:00,SGEN,neutral
1128724.0,Form 8-K from Seattle Genetics Shows Co. Expecting Adcetris Phase 3 Athera Data in 2H,2014-05-01 16:22:00-04:00,SGEN,neutral
1128725.0,"Seattle Genetics, Inc. Reports Q1 EPS of $(0.13) vs $(0.21) Est; Revenue of $68.30M vs $64.62M Est",2014-05-01 16:06:00-04:00,SGEN,neutral
1128726.0,"Option Alert: Seattle Genetics Jun $65 Call; 5,000 Contracts Traded vs 5,213 OI; Currently $39.79",2014-04-11 12:51:00-04:00,SGEN,positive
1128727.0,Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS,2014-04-08 09:02:00-04:00,SGEN,neutral
1128728.0,"Seattle Genetics CEO Siegall: ''We are First and Foremost a Drug Company, But We Also Partner Our Technology with Other Companies'",2014-03-19 18:51:00-04:00,SGEN,neutral
1128729.0,Seattle Genetics CEO Siegall: 'ADCETRIS is Approved in 39 Countries',2014-03-19 18:50:00-04:00,SGEN,positive
1128730.0,Seattle Genetics CEO Siegall: 'We have a Lot of Different Trials',2014-03-19 18:49:00-04:00,SGEN,neutral
1128731.0,Jim Cramer Interviews CEO  Dr. Clay B. Siegall of Seattle Genetics on Mad Money,2014-03-19 18:48:00-04:00,SGEN,negative
1128732.0,UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris,2014-03-10 09:20:00-04:00,SGEN,positive
1128733.0,"HC Wainwright Initiates Coverage on Seattle Genetics, Inc. at Buy, Announces $65.00 PT",2014-03-10 07:51:00-04:00,SGEN,neutral
1128734.0,Article in UK Daily Mail on Seattle Genetics' Adcetris (Brentuximab),2014-02-25 10:37:00-05:00,SGEN,neutral
1128735.0,UPDATE: Bank of America Reinstates Coverage on Seattle Genetics as High Expectations are Priced In,2014-02-24 08:37:00-05:00,SGEN,neutral
1128736.0,"Bank of America Reinstates Underperform on Seattle Genetics, Inc., Announces $46.00 PO",2014-02-24 07:08:00-05:00,SGEN,negative
1128737.0,"Market Wrap For February 12: Markets Take a Breather, Senate Passes Debt Limit Bill",2014-02-12 16:59:00-05:00,SGEN,negative
1128738.0,"Needham Upgrades Seattle Genetics, Inc. to Buy",2014-02-12 07:41:00-05:00,SGEN,neutral
1128739.0,"Seattle Genetics, Inc. Reports Q4 EPS of $(0.13) vs $(0.24) Est; Revenue of $67.40M vs $59.27M Est",2014-02-11 16:08:00-05:00,SGEN,neutral
1128740.0,Seattle Genetics Hits $5M Sales Milestone Under ADCETRIS,2014-02-05 09:02:00-05:00,SGEN,neutral
1128741.0,"UPDATE: Seattle Genetics Japanese Approval Triggers Milestone Payments of $9M, Will Receive Two Milestone Payments from Takeda",2014-01-17 09:02:00-05:00,SGEN,positive
1128742.0,Seattle Genetics Announces ADCETRIS Approval in Japan,2014-01-17 09:00:00-05:00,SGEN,positive
1128743.0,Seattle Genetics Expecting Data from Phase 3 ADCETRIS Study Released During 2H'14,2014-01-13 12:32:00-05:00,SGEN,neutral
1128744.0,UPDATE: Seattle Genetics May Get Up to $255M in License Fees,2014-01-08 09:03:00-05:00,SGEN,neutral
1128745.0,"Seattle Genetics Expands Antibody-Drug Conjugate Pact with AbbVie, to Get $25M Upfront",2014-01-08 09:02:00-05:00,SGEN,positive
1128746.0,"Office Depot, Seattle Genetics And Others Insiders Have Been Buying",2013-12-21 17:02:00-05:00,SGEN,neutral
1128747.0,"Seattle, Genetics Takeda Highlight Long-term Follow-up Data from ADCETRIS Pivotal Clinical Trials   at ASH",2013-12-09 11:27:00-05:00,SGEN,positive
1128748.0,"Seattle Genetics, International Speedway And Others Insiders Have Been Buying",2013-12-09 07:02:00-05:00,SGEN,neutral
1128749.0,Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013 ,2013-12-07 11:03:00-05:00,SGEN,positive
1128750.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,SGEN,positive
1128751.0,"Seattle Genetics, Inc. Reports Q3 EPS of $(0.19) vs $(0.22) Est; Revenue of $71.0M vs $57.79M Est",2013-11-05 16:46:00-05:00,SGEN,neutral
1128752.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,SGEN,positive
1128753.0,Seattle Genetics Initiates Phase 1 LIV-1-Positive Metastatic Breast Cancer Trial of SGN-LIV1A,2013-10-21 09:17:00-04:00,SGEN,negative
1128754.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,SGEN,neutral
1128755.0,"UBS Maintains Neutral on Seattle Genetics, Inc., Raises PT to $48.00",2013-10-08 10:54:00-04:00,SGEN,neutral
1128756.0,Seattle Genetics Names Jonathan Drachman Chief Medical Officer,2013-10-02 09:03:00-04:00,SGEN,neutral
1128757.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,SGEN,positive
1128758.0,UODATE: Seattle Genetics FDA orphan Designation is for Adcetris for Treatment for Patients with Angioimmunoblastic T-cell Lymphoma,2013-09-19 13:09:00-04:00,SGEN,neutral
1128759.0,Seattle Genetics Gets FDA Orphan Designation for Adcetris to Treat Angioimmunoblastic T-Cell Lymphoma,2013-09-19 13:03:00-04:00,SGEN,positive
1128760.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,SGEN,positive
1128761.0,Seattle Genetics CEO Siegall: 'We Have 12 Partners and Do 1 to 2 Partnerships a Year',2013-09-09 19:17:00-04:00,SGEN,neutral
1128762.0,"Seattle Genetics CEO Siegall: 'T-Cell Lymphoma is Typically Trated with a 4-Drug Cocktail, Our Therapy is a 2-Drug Therapy and Double the Success Rate'",2013-09-09 19:16:00-04:00,SGEN,positive
1128763.0,Seattle Genetics CEO Siegall: ''We Have Over 20 Clinical Trials',2013-09-09 19:14:00-04:00,SGEN,neutral
1128764.0,Jim Cramer Interviews CEO Dr. Clay B. Siegall of Seattle Genetics on Mad Money,2013-09-09 19:13:00-04:00,SGEN,negative
1128765.0,"Jefferies Maintains Buy on Seattle Genetics, Inc., Raises PT to $45.00",2013-08-01 09:21:00-04:00,SGEN,neutral
1128766.0,"Seattle Genetics, Inc. Reports Q2 EPS of $(0.06) vs $(0.19) Est; Revenue of $73.60M vs $57.15M Est",2013-07-31 16:47:00-04:00,SGEN,neutral
1128767.0,"Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)",2013-07-02 08:58:00-04:00,SGEN,neutral
1128768.0,Bernstein Believes Onyx Pharma Bid Would Need to be in $140-150/Share Range to Sufficiently Entice Management,2013-07-01 12:38:00-04:00,SGEN,neutral
1128769.0,"Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration",2013-06-27 09:04:00-04:00,SGEN,neutral
1128770.0,"Recent Upside in Seattle Genetics Shares Being Attributed to Credit Suisse Defense, Says Concerns 'Overstated'",2013-06-25 12:53:00-04:00,SGEN,positive
1128771.0,"Hearing Merrill Spoke with Seattle Genetics Management, Says Pancreatitis Looks Like 1-Time Event, Not Caused by Adcetris  ",2013-06-25 12:08:00-04:00,SGEN,positive
1128772.0,Seattle Genetics Halts Study of Lymphoma Drug Due to Safety Concerns -TheStreet,2013-06-25 10:18:00-04:00,SGEN,positive
1128773.0,Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer ,2013-06-25 07:04:00-04:00,SGEN,neutral
1128774.0,Hearing Seattle Genetics CEO  Says Not Aware Of Pancreatitis Causing Any Adcetris Study To Be Halted; No Company-Run Adcetris Trials Halted For Any Toxicity,2013-06-21 14:23:00-04:00,SGEN,negative
1128775.0,Hearing JMP Confirms Investigator at Lugano Conferecne Said Seattle Genetics'  Adcetris+Rituxan Study Might be Stopped Due to Pancreatitis,2013-06-21 11:54:00-04:00,SGEN,negative
1128776.0,Seattle Genetics to Issue Clinical Data on ADCETRIS at ICML,2013-06-21 09:05:00-04:00,SGEN,neutral
1128777.0,"Takeda, Seattle Genetics Report Data for Adcetris in Malignant Lymphoma Compared to Prior Theropy",2013-06-19 09:05:00-04:00,SGEN,neutral
1128778.0,UPDATE: Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse ,2013-06-10 09:17:00-04:00,SGEN,neutral
1128779.0,Seattle Genetics Announces Commencement of  Phase 1/2 Trial of ADCETRIS Combo with Bendamustine,2013-06-10 09:00:00-04:00,SGEN,neutral
1128780.0,Seattle Genetics Highlights ADCETRIS Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate Collaborator Data at ASCO,2013-06-02 09:10:00-04:00,SGEN,neutral
1128781.0,Seattle Genetics Announces ADCETRIS Supplemental BLA Accepted for Filing by the FDA ,2013-05-14 09:03:00-04:00,SGEN,positive
1128782.0,"Seattle Genetics, Inc. Reports Q1 EPS of $(0.14) vs $(0.20) Est; Revenue of $57.30M vs $53.72M Est",2013-05-07 16:42:00-04:00,SGEN,neutral
1128783.0,"Goldman Sachs Reinstates Neutral on Seattle Genetics, Inc., Announces $37.00 PT",2013-05-07 06:46:00-04:00,SGEN,neutral
1128784.0,Three Top Performing Healthcare Stocks to Watch,2013-05-06 15:53:00-04:00,SGEN,positive
1128785.0,Stocks Hitting 52-Week Highs,2013-03-26 10:45:00-04:00,SGEN,neutral
1128786.0,"Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)",2013-03-23 11:33:00-04:00,SGEN,positive
1128787.0,Stocks Hitting 52-Week Highs,2013-03-22 11:08:00-04:00,SGEN,neutral
1128788.0,"Seattle Genetics Submits Supplemental BLA to FDA for Retreatment, Extended Duration of Therapy with ADCETRIS",2013-03-18 09:00:00-04:00,SGEN,neutral
1128789.0,"Needham Downgrades Seattle Genetics, Inc. to Hold, Removes $25.00 Pt",2013-02-13 07:42:00-05:00,SGEN,neutral
1128790.0,"Seattle Genetics, Inc. Reports Q4 EPS of $(0.09) vs $(0.11) Est; Revenue of $63.90M vs $57.21M Est",2013-02-12 16:07:00-05:00,SGEN,neutral
1128791.0,Seattle Genetics Commences Two Phase I Trials of SGN-CD19A,2013-02-06 09:03:00-05:00,SGEN,neutral
1128792.0,"Seattle Genetics' ADCETRIS Approved by Health Canada for Treatment of Relapsed, Refractory HL, sALCL",2013-02-01 14:11:00-05:00,SGEN,positive
1128793.0,Seattle Genetics Offers Data from ASG-5ME Phase I Trial,2013-01-25 09:04:00-05:00,SGEN,neutral
1128794.0,Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL) ,2013-01-24 09:02:00-05:00,SGEN,positive
1128795.0,Seattle Genetics Spikes Higher,2013-01-22 14:34:00-05:00,SGEN,neutral
1128796.0,Seattle Genetics Offers Data on Next-Gen Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting,2012-12-10 10:03:00-05:00,SGEN,neutral
1128797.0,Seattle Genetics Presents Encouraging ADCETRIS Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies,2012-12-09 11:07:00-05:00,SGEN,positive
1128798.0,Seattle Genetics Confirms FDA Orphan Drug Status for ADCETRIS,2012-11-26 09:03:00-05:00,SGEN,neutral
1128799.0,Seattle Genetics Receives FDA Orphan Drug Status for Mycosis Fungoides - Bloomberg,2012-11-20 11:04:00-05:00,SGEN,neutral
1128800.0,UPDATE: Credit Suisse Initiates Seattle Genetics at Outperform; Antubody Pure-Play  ,2012-11-13 13:39:00-05:00,SGEN,positive
1128801.0,"Credit Suisse Initiates Coverage on Seattle Genetics /wa at Outperform, Announces PT of $28",2012-11-12 16:24:00-05:00,SGEN,positive
1128802.0,"UBS Maintains Seattle Genetics /wa at Neutral, Lowers PT from $30 to $27",2012-11-08 14:48:00-05:00,SGEN,negative
1128803.0,Seattle Genetics Falls After Q3 Results and Analyst Downgrade,2012-11-08 14:26:00-05:00,SGEN,neutral
1128804.0,"Oppenheimer Maintains Seattle Genetics /wa at Perform, Lowers PT from $27 to $23",2012-11-08 08:50:00-05:00,SGEN,negative
1128805.0,Seattle Genetics /wa Reports Q3 EPS $-0.12 vs $-0.15 Est; Revenues $49.8M vs $52.66M Est,2012-11-07 16:25:00-05:00,SGEN,neutral
1128806.0,"Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS",2012-11-01 08:17:00-04:00,SGEN,neutral
1128807.0,Seattle Genetics Announces EC Conditional Marketing Authorization ADCETRIS,2012-10-31 07:06:00-04:00,SGEN,neutral
1128808.0,Seattle Genetics Expands Antibody-Drug Pact with Abbott -Bloomberg,2012-10-23 09:05:00-04:00,SGEN,positive
1128809.0,Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS,2012-10-17 09:02:00-04:00,SGEN,neutral
1128810.0,Seattle Genetics Will Get Undisclosed Milestone Payments,2012-10-09 09:01:00-04:00,SGEN,neutral
1128811.0,"UBS Maintains Seattle Genetics /wa at Neutral, Raises PT from $24 to $30",2012-09-10 12:03:00-04:00,SGEN,neutral
1128812.0,Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75,2012-08-24 09:07:00-04:00,SGEN,neutral
1128813.0,Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma,2012-08-24 09:04:00-04:00,SGEN,neutral
1128814.0,"Cantor Fitzgerald Initiates Coverage Seattle Genetics /wa at Hold, Announces PT of $30",2012-08-20 16:11:00-04:00,SGEN,neutral
1128815.0,"Oppenheimer Maintains Seattle Genetics /wa at Outperform, Raises PT from $26 to $28",2012-08-09 11:55:00-04:00,SGEN,neutral
1128816.0,"UBS Maintains Seattle Genetics /wa at Neutral, Raises PT from $23 to $24",2012-08-09 10:21:00-04:00,SGEN,neutral
1128817.0,Seattle Genetics /wa Reports Q2 EPS $-0.15 vs $-0.15 Est; Revenues $48.8M vs $50.33M Est,2012-08-08 16:09:00-04:00,SGEN,neutral
1128818.0,Seattle Genetics /wa Reports Q2 EPS $-0.15 vs $-0.15 Est; Revenues $48.8M vs $50.33M Est,2012-08-08 16:09:00-04:00,SGEN,neutral
1128819.0,Seattle Genetics Announces ADCETRIS Receives Positive CHMP Opinion for Conditional Approval in European Union   ,2012-07-20 10:47:00-04:00,SGEN,positive
1128820.0,Seattle Genetics Rises to 52-Week High on CHMP Positive Opinion on Adcertis,2012-07-20 10:16:00-04:00,SGEN,positive
1128821.0,Benzinga's Top Initiations,2012-07-05 08:31:00-04:00,SGEN,positive
1128822.0,"ThinkEquity Initiates Seattle Genetics at Buy, Initiates PT to $30",2012-07-05 07:34:00-04:00,SGEN,neutral
1128823.0,UPDATE: Piper Jaffray Downgrades Seattle Genetics to Underweight on Limited Sales Growth Outlook  ,2012-07-02 07:40:00-04:00,SGEN,positive
1128824.0,"Piper Jaffray Downgrades Seattle Genetics /wa from Neutral to Underweight, Lowers PT from $22 to $20",2012-07-02 05:56:00-04:00,SGEN,negative
1128825.0,Seattle Genetics Highlights Updated Survival Data from ADCETRIS® Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma   ,2012-06-14 07:01:00-04:00,SGEN,neutral
1128826.0,"Few trade ideas for tomorrow, June 14th",2012-06-13 17:23:00-04:00,SGEN,neutral
1128827.0,Seattle Genetics Trading 1.4% Higher on Heavy Volume; Currently at $22.73,2012-06-08 10:09:00-04:00,SGEN,neutral
1128828.0,Seattle Genetics CEO Siegall: 'We Are Developing 7 Products that Target Different Types of Tumors',2012-06-05 18:51:00-04:00,SGEN,neutral
1128829.0,Seattle Genetics CEO Siegall: 'This isn't Like Standard Chemotherapy; Patients Feel Much Better from Our Treatment',2012-06-05 18:50:00-04:00,SGEN,positive
1128830.0,Jim Cramer Interviews CEO Dr. Clay B. Siegall of Seattle Genetics on Mad Money,2012-06-05 18:48:00-04:00,SGEN,negative
1128831.0,PREVIEW: Jim Cramer to Interview CEO of Seattle Genetics on Mad Money,2012-06-05 18:11:00-04:00,SGEN,negative
1128832.0,Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer,2012-06-04 09:03:00-04:00,SGEN,negative
1128833.0,UPDATE: Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review   ,2012-05-23 09:02:00-04:00,SGEN,positive
1128834.0,Seattle Genetics Reports Health Canada Accepts Adcetris,2012-05-23 09:00:00-04:00,SGEN,positive
1128835.0,Seattle Genetics Announces Data from Investigator Trial of ADCETRIS in Relapsed Cutaneous T-Cell Lymphoma; Data Demonstrate 75 Percent Response Rate in Patients with Relapsed CTCL  ,2012-05-10 10:01:00-04:00,SGEN,neutral
1128836.0,Seattle Genetics /wa Reports Q1 EPS $-0.11 vs $-0.12 Est; Revenues $48.2M vs $52.33M Est,2012-05-08 16:07:00-04:00,SGEN,neutral
1128837.0,"Option Alert: Seattle Genetics May 22.5 Call; Block Trade: 1,543 Contracts; Currently $19.97",2012-04-30 09:48:00-04:00,SGEN,negative
1128839.0,Notable Call Options Activity in Seattle Genetics,2012-03-21 10:17:00-04:00,SGEN,neutral
1128840.0,Seattle Genetics Reports Q4 EPS $(0.24) vs $(0.31) Est; Revenues $48.90M vs $39.12M Est	 		,2012-02-13 16:05:00-05:00,SGEN,neutral
1128841.0,Notable Put Options Activity in Seattle Genetics,2012-02-13 11:35:00-05:00,SGEN,neutral
1128842.0,Bank of America Optimistic Over Seattle Genetics' Adcetris,2012-01-30 08:32:00-05:00,SGEN,positive
1128843.0,"Benzinga's M&A Chatter for Thursday January 26, 2012",2012-01-26 18:24:00-05:00,SGEN,neutral
1128844.0,Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma  ,2012-01-26 16:04:00-05:00,SGEN,neutral
1128845.0,Seattle Genetics Spokesperson Would Not Comment on Earlier Merck Takeover Rumor,2012-01-26 12:01:00-05:00,SGEN,neutral
1128846.0,Positive Rumors Circulate About Seattle Genetics /wa,2012-01-26 10:15:00-05:00,SGEN,positive
1128847.0,Seattle Genetics /wa Trading 4.1% Higher on Heavy Volume; Currently at $19.08,2012-01-26 10:14:00-05:00,SGEN,neutral
1128848.0,"Oppenheimer Reiterates Outperform, $26 PT On Seattle Genetics",2012-01-13 14:12:00-05:00,SGEN,neutral
1128849.0,A Peek Into The Market Before The Trading Starts,2012-01-13 07:24:00-05:00,SGEN,neutral
1128850.0,Seattle Genetics Announces Updates to ADCETRIS Prescribing Information   ,2012-01-13 06:45:00-05:00,SGEN,neutral
1128851.0,JPMorgan Confab Kicks Off Biotech 2012,2012-01-05 11:46:00-05:00,SGEN,neutral
1128852.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,SGEN,positive
1128853.0,"Benzinga's M&A Chatter for Thursday December 15, 2011",2011-12-15 17:47:00-05:00,SGEN,neutral
1128854.0,Seattle Genetics Says Drug Well Tolerated as Initial Treatment for Hodgkin's Lymphoma,2011-12-13 10:30:00-05:00,SGEN,positive
1128855.0,Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting   ,2011-12-12 13:30:00-05:00,SGEN,positive
1128856.0,Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS at ASH Annual Meeting   ,2011-12-12 13:00:00-05:00,SGEN,neutral
1128857.0,Five Biotech Stocks to Watch Going into Big Doctors' Meeting,2011-12-09 13:06:00-05:00,SGEN,neutral
1128858.0,Investor Ideas' Thursday's Biotech Stocks to Watch,2011-12-09 12:22:00-05:00,SGEN,neutral
1128859.0,Investor Ideas' Thursday's Biotech Stocks to Watch,2011-12-09 11:47:00-05:00,SGEN,neutral
1128860.0,Why Biotech Investors Must Understand the FDA's Adverse Events Reports,2011-12-07 11:40:00-05:00,SGEN,negative
1128861.0,Jefferies Maintains Buy Rating and $28 PT on Seattle Genetics ,2011-12-02 08:18:00-05:00,SGEN,neutral
1128862.0,"Seattle Genetics Down over 3.5%, May be Attributed to Analyst Call on Adverse Affects on Drug",2011-12-01 11:13:00-05:00,SGEN,negative
1128863.0,Top Movers; MedAssets up 17%,2011-11-04 16:12:00-04:00,SGEN,positive
1128864.0,UPDATE: JP Morgan Raises PT to $16 on Seattle Genetics ,2011-11-04 08:43:00-04:00,SGEN,positive
1128865.0,UPDATE: Piper Jaffray Downgrades Seattle Genetics to Neutral,2011-11-04 08:00:00-04:00,SGEN,neutral
1128866.0,JP Morgan Raises PT on Seattle Genetics to $16,2011-11-04 07:16:00-04:00,SGEN,positive
1128867.0,Seattle Genetics Reports Q3 EPS $(0.35) vs $(0.46) Est; Revenues $20.7M vs $13.57M Est		,2011-11-03 16:27:00-04:00,SGEN,neutral
1128868.0,Jefferies Maintains Buy Rating and $25 PT on Seattle Genetics ,2011-10-31 09:52:00-04:00,SGEN,neutral
1128869.0,Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Lymphoma Malignancies  ,2011-10-25 09:01:00-04:00,SGEN,neutral
1128870.0,"Bank of America Raises PO On Seattle Genetics to $22, Maintains Buy",2011-10-18 13:11:00-04:00,SGEN,negative
1128871.0,"UBS Changes PT on ADTN, VRUS, SGEN",2011-10-13 11:04:00-04:00,SGEN,neutral
1128872.0,Jefferies Maintains Buy Rating and $25 PT on Seattle Genetics,2011-10-12 09:09:00-04:00,SGEN,neutral
1128873.0,Goldman Sachs Resumes Seattle Genetics at Neutral,2011-10-03 07:20:00-04:00,SGEN,neutral
1128874.0,"Goldman Sachs Resumes Seattle Genetics at Neutral, $20 PT",2011-10-03 05:51:00-04:00,SGEN,neutral
1128875.0,Midday Gainers; Pandora up Nearly 7%,2011-09-19 12:47:00-04:00,SGEN,neutral
1128876.0,Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer   ,2011-09-13 07:01:00-04:00,SGEN,negative
1128877.0,Eight Stocks Insiders Are Buying,2011-09-12 06:46:00-04:00,SGEN,neutral
1128878.0,Pre-Market Movers,2011-08-30 08:53:00-04:00,SGEN,neutral
1128879.0,UPDATE: Bank Of America Raises Price Target On Seattle Genetics To $19,2011-08-30 07:37:00-04:00,SGEN,neutral
1128880.0,Bank of America Raises PO On Seattle Genetics To $19,2011-08-30 06:14:00-04:00,SGEN,negative
1128881.0,Notable Put Options Activity in Seattle Genetics,2011-08-29 10:57:00-04:00,SGEN,neutral
1128882.0,UPDATE: Bank of America Lowers PT on Seattle Genetics from $18 to $17,2011-08-23 09:58:00-04:00,SGEN,negative
1128883.0,Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Hodgkin Lymphoma ,2011-08-23 09:00:00-04:00,SGEN,neutral
1128884.0,UPDATE: Siegall Claims Adcetris Targets Cancer Cells and Efficiently Kills Cancer Cells Alone; Says Drug is Unique in this Aspect and is First Drug for Hodgkin's Lymphoma in 30 Years,2011-08-22 11:27:00-04:00,SGEN,negative
1128885.0,Seattle Genetics CEO Siegall Says Price of Adcentris is Priced in Right Way,2011-08-22 11:26:00-04:00,SGEN,neutral
1128886.0,UPDATE: Seattle Genetics New Drug Priced at $13.5K/Dose; Siegall Defends its Price as a Function of Efficacy and Sustainability,2011-08-22 11:26:00-04:00,SGEN,neutral
1128887.0,Seattle Genetics CEO Clay Siegall Speaking on CNBC,2011-08-22 11:25:00-04:00,SGEN,neutral
1128888.0,Jefferies Comments on Seattle Genetics After Approval of Adcetris,2011-08-22 09:14:00-04:00,SGEN,positive
1128889.0,Piper Jaffray Overweight On Seattle Genetics,2011-08-22 08:00:00-04:00,SGEN,negative
1128890.0,UPDATE: Hearing Canaccord's George Farmer is Short in Seattle Genetics,2011-08-19 14:54:00-04:00,SGEN,neutral
1128891.0,Hearing Cannacord Says Sell Seattle Genetics into Strength,2011-08-19 14:42:00-04:00,SGEN,positive
1128892.0,UPDATE: Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications ,2011-08-19 14:08:00-04:00,SGEN,positive
1128893.0,Seattle Genetics Receives FDA Approval on Lymphoma Drug,2011-08-19 13:54:00-04:00,SGEN,positive
1128894.0,Seattle Genetics Spiking Higher on FDA Approval of Adcetris,2011-08-19 13:54:00-04:00,SGEN,positive
1128895.0,UPDATE: Citadel Securities Initiates Coverage on Seattle Genetics,2011-08-08 06:56:00-04:00,SGEN,positive
1128896.0,"Citadel Initiates Seattle Genetics At Reduce, $10 PT",2011-08-08 06:08:00-04:00,SGEN,neutral
1128897.0,UPDATE: William Blair Reiterates Outperform on Seattle Genetics,2011-07-21 09:19:00-04:00,SGEN,neutral
1128898.0,Canaccord Genuity Maintains Sell Rating on Seattle Genetics with $10 PT,2011-07-19 08:14:00-04:00,SGEN,neutral
1128899.0,Seattle Genetics Down 9% on Heavy Volume,2011-07-15 09:50:00-04:00,SGEN,neutral
1128900.0,UPDATE: Jefferies Raises PT on Seattle Genetics to $25,2011-07-15 08:58:00-04:00,SGEN,neutral
1128901.0,UPDATE: Oppenheimer Raising Its Price Target On Seattle Genetics (SGEN,2011-07-15 08:50:00-04:00,SGEN,neutral
1128902.0,UPDATE: Seattle Genetics Confident FDA Pact Will be Agreed to Before Aug 30 PDUFA Date,2011-07-15 08:42:00-04:00,SGEN,positive
1128903.0,Seattle Genetics Working on FDA Agreement for Confirmatory Studies,2011-07-15 08:41:00-04:00,SGEN,positive
1128904.0,UPDATE: Oppenheimer Raises PT on Seattle Genetics to $24,2011-07-15 07:37:00-04:00,SGEN,neutral
1128905.0,Seattle Genetics Trading Down Over 4.50% After FDA Announced It Would Speed Up Approval of the Company's Cancer Drug,2011-07-15 07:24:00-04:00,SGEN,negative
1128906.0,Jefferies Raises PT On Seattle Genetics To $25,2011-07-15 07:19:00-04:00,SGEN,neutral
1128907.0,Oppenheimer Raises PT On Seattle Genetics To $24,2011-07-15 06:10:00-04:00,SGEN,neutral
1128908.0,PREVIEW: Seattle Genetics to Resume Trading at 5:05 p.m.,2011-07-14 16:50:00-04:00,SGEN,neutral
1128909.0,Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee,2011-07-14 16:34:00-04:00,SGEN,neutral
1128910.0,Update On Seattle Genetics FDA Meeting,2011-07-14 15:01:00-04:00,SGEN,neutral
1128912.0,Biggest Gainers Pre-Market Going Into the Opening Bell,2011-07-14 09:20:00-04:00,SGEN,neutral
1128913.0,Last  Nights Noteables July 14th,2011-07-14 08:44:00-04:00,SGEN,neutral
1128914.0,A Peek Into The Market Before The Trading Starts,2011-07-14 07:33:00-04:00,SGEN,neutral
1128915.0,UPDATE: Seattle Genetics Common Stock Halted; FDA to Discuss Company's Application for ADCETRIS  ,2011-07-14 07:10:00-04:00,SGEN,neutral
1128916.0,"Seattle Genetics Halted, Pending News",2011-07-14 07:01:00-04:00,SGEN,neutral
1128917.0,Summer Swing  07-13-2011,2011-07-13 18:05:00-04:00,SGEN,neutral
1128918.0,"Dollar down, Market up  07-13-2011",2011-07-13 15:11:00-04:00,SGEN,neutral
1128919.0,Puts Purchased on Seattle Genetics,2011-07-13 11:00:00-04:00,SGEN,neutral
1128920.0,Bank of America Merrill Lynch Discusses Seattle Genetics After FDA Briefing,2011-07-12 12:28:00-04:00,SGEN,neutral
1128921.0,Jefferies Says Buy Seattle Genetics,2011-07-12 12:24:00-04:00,SGEN,neutral
1128922.0,Options Brief: Seattle Genetics,2011-07-08 11:12:00-04:00,SGEN,neutral
1128923.0,Piper Jaffray Reiterates OW Rating on Seattle Genetics,2011-07-06 07:34:00-04:00,SGEN,neutral
1128924.0,Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows,2011-06-29 04:11:00-04:00,SGEN,positive
1128925.0,Seattle Genetics Achieves $5M Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA ,2011-06-27 07:01:00-04:00,SGEN,positive
1128926.0,"Mad Money Lightning Round OT: Cramer Is A Buyer Of SGEN, IBM, ANR",2011-06-22 19:06:00-04:00,SGEN,negative
1128927.0,Stocks to Watch for 6/21/11: Fresh 52 Week Highs and Lows,2011-06-21 04:09:00-04:00,SGEN,positive
1128928.0,Seattle Genetics Announces Promotion of Eric Dobmeier to COO,2011-06-17 12:30:00-04:00,SGEN,neutral
1128929.0,Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL ,2011-06-16 08:52:00-04:00,SGEN,neutral
1128930.0,Piper Jaffray Reiterates Overweight Rating On Seattle Genetics,2011-06-13 08:35:00-04:00,SGEN,negative
1128931.0,Jefferies Maintains Buy on Seattle Genetics,2011-06-07 07:40:00-04:00,SGEN,neutral
1128932.0,Seattle Genetics Presents SGN-75 Clinical Data Suggesting It Is Well Tolerated  ,2011-06-06 09:03:00-04:00,SGEN,positive
1128933.0,Bank Of America Comments On Seattle Genetics Regulatory Discussions,2011-06-06 08:04:00-04:00,SGEN,neutral
1128934.0,Jefferies Provides Color on Seattle Genetics ,2011-06-06 07:46:00-04:00,SGEN,neutral
1128935.0,"Options Brief: Seattle Genetics, Inc.",2011-05-25 11:11:00-04:00,SGEN,neutral
1128936.0,J.P. Morgan Maintains Neutral Rating On SGEN,2011-05-02 09:57:00-04:00,SGEN,neutral
1128937.0,UPDATE: Seattle Genetics Trading Higher Pre-Market After FDA News (SGEN),2011-05-02 08:59:00-04:00,SGEN,neutral
1128938.0,Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Review for Hodgkin Lymphoma and Systemic ALCL (SGEN),2011-05-02 07:40:00-04:00,SGEN,positive
1128939.0,Hoo-ah! Five Stocks to Consider on Al Pacino's Birthday,2011-04-25 11:54:00-04:00,SGEN,neutral
1128940.0,Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development   ,2011-04-13 09:06:00-04:00,SGEN,neutral
1128941.0,Brean Murray Carret Reiterates Sell Rating On Seattle Genetics,2011-04-12 07:18:00-04:00,SGEN,neutral
1128942.0,Seattle Genetics Reports Brentuximab Vedotin Data at EBMT Annual Meeting ,2011-04-06 08:05:00-04:00,SGEN,neutral
1128943.0,Seattle Genetics Reports All Patients Relapsed After Lymphoma Trial Transplant (SGEN),2011-04-06 08:04:00-04:00,SGEN,neutral
1128944.0,Seattle Genetics Highlights ADC Technology Research at AACR   ,2011-04-05 08:11:00-04:00,SGEN,neutral
1128945.0,"Mad Money Lightning Round: Cramer Likes CB Richard Ellis (SGEN, CBG, BIDU, SINA, ACW, CNH, POT)",2011-03-25 00:41:00-04:00,SGEN,negative
1128946.0,Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott   ,2011-03-22 09:01:00-04:00,SGEN,neutral
1128947.0,Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy,2011-03-01 08:13:00-05:00,SGEN,neutral
1128948.0,Jefferies Initiates Seattle Genetics at Buy (SGEN),2011-02-17 10:15:00-05:00,SGEN,neutral
1128949.0,Jefferies Raises PT On Seattle Genetics To $22,2011-02-17 08:09:00-05:00,SGEN,neutral
1128950.0,Piper Jaffray Comments On Seattle Genetics Following Earnings Report,2011-02-09 08:56:00-05:00,SGEN,neutral
1128951.0,Oppenheimer Has Outperform On Seattle Genetics (SGEN),2011-02-09 07:33:00-05:00,SGEN,neutral
1128952.0,Oppenheimer Raises PT On Seattle Genetics To $17,2011-02-09 06:57:00-05:00,SGEN,neutral
1128953.0,Seattle Genetics Prices 10M Share Offering at $15.50,2011-02-02 09:03:00-05:00,SGEN,positive
1128954.0,Seattle Genetics Announces Proposed Public Offering  ,2011-02-01 16:35:00-05:00,SGEN,neutral
1128955.0,"Calls Purchased on Seattle Genetics, Inc. (SGEN)",2011-01-27 10:36:00-05:00,SGEN,neutral
1128956.0,Piper Jaffray Reiterates Overweight Rating on Seattle Genetics (SGEN),2011-01-19 07:55:00-05:00,SGEN,negative
1128957.0,Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN),2011-01-11 13:46:00-05:00,SGEN,neutral
1128958.0,J.P. Morgan Healthcare Confab: Live Blog,2011-01-11 09:55:00-05:00,SGEN,neutral
1128959.0,Biotech Stock Mailbag: Best Stocks to Watch in '11,2011-01-07 07:00:00-05:00,SGEN,positive
1128960.0,Seattle Genetics Announces Collaboration with Pfizer   ,2011-01-06 07:41:00-05:00,SGEN,neutral
1128961.0,"Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)",2011-01-05 07:50:00-05:00,SGEN,positive
1128962.0,15 Biotech Stock Predictions for 2011,2010-12-15 07:02:00-05:00,SGEN,neutral
1128963.0,Biotech Sector Weekly Rewind,2010-12-11 08:10:00-05:00,SGEN,neutral
1128964.0,J.P. Morgan Reiterates Neutral Rating on Seattle Genetics (SGEN),2010-12-06 09:34:00-05:00,SGEN,neutral
1128965.0,Seattle Genetics and Millennium to Present Brentuximab Vedotin Clinical Data ,2010-11-08 10:46:00-05:00,SGEN,neutral
1128966.0,JP Morgan Downgrades SGEN To Neutral,2010-11-02 07:19:00-04:00,SGEN,positive
1128967.0,Seattle Genetics Reports Third Quarter EPS of $(0.34),2010-11-01 16:17:00-04:00,SGEN,neutral
1128968.0,"Price Target Changes On SGEN, FFIV, EBAY",2010-10-12 10:39:00-04:00,SGEN,neutral
1128969.0,"NASDAQ Stocks Hitting 52-Week Highs (ACTL, SGEN, SIRI, DDMX)",2010-10-04 11:49:00-04:00,SGEN,neutral
1128970.0,"Benzinga's Top Pre-Market NASDAQ Gainers (SGEN, CADC, GERN, CRUS) ",2010-09-29 08:53:00-04:00,SGEN,positive
1128971.0,"Benzinga's Top Upgrades (PHM, LVS, SGEN, APSG)",2010-09-28 07:27:00-04:00,SGEN,positive
1128972.0,SGEN Announces Favorable SGN-35 Results; Shares Up,2010-09-27 14:18:00-04:00,SGEN,positive
1128973.0,"Biotech Stocks Trading High Volume (UVFT.OB, KBLB.OB, SGEN, GENZ)",2010-09-27 14:09:00-04:00,SGEN,neutral
1128974.0,"Benzinga's Volume Movers (SGEN, HMIN, BIDU, ATPG)",2010-09-27 12:17:00-04:00,SGEN,neutral
1128975.0,"Benzinga's Top Pre-Market NASDAQ Gainers (SGEN, JBLU, GFRE, ATPG)",2010-09-27 09:04:00-04:00,SGEN,positive
1128976.0,Biotechnology Stock News; Seattle Genetics (Nasdaq: SGEN) and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lym,2010-09-27 09:00:00-04:00,SGEN,positive
1128977.0,Biotechnology Stock News; Seattle Genetics (Nasdaq: SGEN) and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lym,2010-09-27 09:00:00-04:00,SGEN,positive
1128978.0,Genmab and Seattle Genetics Enter into Research Collaboration (SGEN),2010-09-14 10:14:00-04:00,SGEN,neutral
1128979.0,"Benzinga's Top Pre-Market NASDAQ Losers (SGEN, ARNA, HGSI, GOLD)",2010-09-13 09:21:00-04:00,SGEN,negative
1128980.0,Seattle Genetics Reports Second Quarter Financial Results,2010-07-27 16:21:00-04:00,SGEN,neutral
1128981.0,Calls Purchased on Seattle Genetics (SGEN),2010-07-01 12:44:00-04:00,SGEN,neutral
1128982.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,SGEN,positive
1128983.0,"Benzinga’s News Roundup (BJ, JOYG, NFLX, SGEN)",2010-03-03 08:11:00-05:00,SGEN,neutral
1128984.0,"Seattle Genetics, Inc.’s (SGEN) Fourth-Quarter Review",2010-02-10 11:47:00-05:00,SGEN,neutral
1128985.0,"Benzinga’s Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)",2009-12-21 08:25:00-05:00,SGEN,positive
1128986.0,"NASDAQ's Most Advanced Today (LIMS, ARRY, SGEN, JASO, JAZZ)",2009-12-15 13:43:00-05:00,SGEN,positive
1128987.0,"Benzinga’s Top Pre- Market Gainers (LIMS, SGEN, CLNE, ARRY, JASO, JAZZ, SPWRA)",2009-12-15 08:39:00-05:00,SGEN,positive
1128988.0,SGEN to Post Mixed Results in 2010,2009-11-30 12:41:00-05:00,SGEN,neutral
1128989.0,"Biggest Losers (CVM, SGEN, SCLN, FOLD, FTBK)",2009-10-05 12:24:00-04:00,SGEN,negative
1128990.0,Two Life Science Companies Manage to Pry Open IPO Window,2009-08-16 06:45:00-04:00,SGEN,neutral
